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1. ABBREVIATIONS 
 
ACE = angiotensin converting enzyme 
ADMA = asymmetric dimethylarginine  
AZA = azathioprine 
BNP = brain natriuretic peptide 
CABG = coronary artery bypass graft 
CAV = cardiac allograft vasculopathy 
CNI  = calcineurin inhibitor 
CRP = C-reactive protein 
CMV = cytomegalovirus 
CSA = cross-sectional area 
ELISA = enzyme linked immunosorbent assay  
EEM = external elastic membrane  
eNOS = endothelial nitric oxide synthase 
GFR = glomerular filtration rate 
HLA = human leucocyte antigen 
HMG-CoA = 3-hydroxy-3methylglutaryl coenzyme A 
HTx = heart transplant/heart transplantation 
ICAM = intercellular adhesion molecule 
IFN- = interferon gamma 
IHD = ischemic heart disease 
IL = interleukin 
IVUS = intravascular ultrasound 
LC = lumen contour 
LDL = low density lipoprotein 
MDRD = Modification of Diet in Renal Disease Study 
MIT = maximal intimal thickness 
MMF = mycophenolate mofetil 
NCC = necrotic core component 
NO = nitric oxide 
NT-proBNP = N-terminal pro-brain natriuretic peptide 
OPG = osteoprotegerin  
PAV = percent atheroma volume 
sTNFR-1 = soluble TNF receptor type 1  
T. gondii = Toxoplasma gondii 
TAV = total atheroma volume 
TNF = tumor necrosis factor 
VCAM-1 = vascular cell adhesion molecule–1 (VCAM-1) 
vWf = von Willebrand factor (vWf) 
VH = virtual histology 
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3. INTRODUCTION 
 
3.1 Cardiac allograft vasculopathy – general aspects 
 
Heart transplantation (HTx) is an established and effective therapy for end-stage heart disease. 
It is estimated that over 5000 HTx procedures are performed annually and the two leading 
etiological causes are heart failure secondary to ischemic heart disease and non-ischemic 
cardiomyopathy (41% and 45%, respectively) (1). In contrast to the first HTx performed in 
1967 where survival was limited to 18 days, the current median survival is reported to be 10 
years (1). Furthermore, the criteria for selection of HTx candidates have evolved with most 
centers now accepting considerably higher-risk patients with multiple comorbidities (2). 
Important surgical advances together with optimal medical therapy are responsible for this 
improvement, but a further reduction in morbidity and mortality remains a significant 
challenge, particularly, due to the development of cardiac allograft vasculopathy (CAV). This 
is a unique form of accelerated atherosclerosis occurring in HTx recipients and is 
characterized by a diffuse, progressive thickening of the arterial intima of both epicardial and 
intramyocardial arteries of the transplanted graft. According to the Registry of the 
International Society for Heart and Lung Transplantation (ISHLT), CAV is detectable in 43% 
of HTx recipients within 8 years after HTx, and accounts for 30% of deaths occurring beyond 
the first year post-HTx (1).  
The pathophysiology of CAV development is not fully clear, but is likely to be 
mulitfactorial with a range of immunological and non-immunological contributors. Although 
the optimal therapeutic strategy to prevent or reverse CAV development remains an elusive 
goal, early and accurate diagnosis of CAV is likely to be critical to further improving outcome 
post-HTx. Most HTx recipients undergo annual angiographic surveillance to detect the 
development and progression of CAV. However, it is well established that this technique has 
insufficient sensitivity to allow accurate CAV detection (3) as the disease is not characterized 
by discrete lesions easily identified by angiography but by diffuse intimal thickening of both 
large and small-caliber vessels. Consequently, alternative methods including intravascular 
ultrasound (IVUS) and measurement of plasma biomarkers are increasingly being considered 
in routine clinical care and may allow appropriate risk stratification and more individualized 
management of patients at higher risk of developing CAV.  Furthermore, accurate 
identification of immunological and non-immunological risk factors contributing to CAV 
development remains an important challenge.  
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3.2 Pathogenesis of cardiac allograft vasculopathy  
 
3.2.1 Histopathological features 
 
Cardiac allograft vasculopathy is typically characterized by a diffuse concentric intimal 
thickening of both epicardial and intramural arteries (4). This is in contrast to native 
atherosclerosis which is typically identified by focal eccentric proliferative lesions of the 
intima of proximal epicardial coronary arteries (Figure 1). Both CAV and atherosclerosis 
consist of fibrofatty plaques that are histopathologically indistinguishable as both lesions 
consist of smooth muscle cell proliferation and accumulation of extracellular lipids (5, 6). 
However, a key difference is that calcium deposition and disruption of the internal elastic 
lamina is rare in CAV but occurs frequently in atherosclerosis. Furthermore, fibrous cap 
thinning together with plaque rupture and formation of complicated plaques (plaques with 
hemorrhage and thrombotic deposits) rarely occur in CAV but are commonly found in native 
atherosclerosis (4). Finally, another important difference is that CAV is characterized by an 
accelerated and rapid progression rate with early intimal changes being evident as early as 1-2 
weeks after HTx and development of lipid-filled cells being evident in the following few 
months after HTx (7).  
 
 
 
 
 
Figure 1.  Typical atherosclerosis versus cardiac allograft vasculopathy.  
Atherosclerosis is characterized by focal lesions whereas diffuse intimal 
thickening is the hallmark of allograft vasculopathy.  
(Reproduced with permission from NEJM (2003), Massachusetts Medical Society.) 
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 Cardiac allograft vasculopathy Native atherosclerosis 
Geometry Diffuse concentric lesions 
Epicardial and intramural arteries 
involved  
Veins may be involved  
Focal eccentric lesions 
Proximal coronary arteries usually 
involved 
Veins rarely involved 
Plaque 
composition 
Smooth muscle cell proliferation, lipid-
filled cells, free lipid deposition 
Calcium deposition and disruption of 
internal elastic lamina is rare 
Fibrous cap thinning, plaque rupture 
and complicated lesions are rare  
Smooth muscle cell proliferation, lipid-
filled cells, free lipid deposition 
Calcium deposition and disruption of 
internal elastic lamina is common 
Fibrous cap thinning, plaque rupture and 
complicated lesions commonly occur 
Time 
progression 
Rapid development and accelerated 
lesion progression (months) 
Slow development and lesion progression 
over years 
 
Table 1. Histopathological features of cardiac allograft vasculopathy as compared to native 
atherosclerosis. 
 
 
Diffuse concentric intimal thickening is considered the hallmark of typical CAV development 
and is often termed negative remodeling as it reduces the lumen diameter. Conversely, 
positive remodeling (compensatory enlargement of vessel wall) processes may also occur 
amongst HTx recipients and counteract or delay the development of luminal obstruction. 
Positive remodeling resulting in an increased  vessel caliber can occur by smooth muscle cell 
turnover and also through extracellular matrix degradation (e.g. via matrix metalloproteinases 
and other proteolytic enzymes) (8). Both intimal hyperplasia and lack of positive remodeling 
can reduce lumen diameter but their relative contribution to CAV development remains 
controversial. Pethig et al. demonstrated that lumen loss is a biphasic process involving early 
intimal thickening (within the first year) and later constrictive remodeling (9). Another larger 
IVUS study found that inadequate compensatory enlargement rather than intimal hyperplasia 
was the major predictor of luminal obstruction (10). Although speculative, it is potentially 
possible that the predominating remodeling pattern is related to underlying pathophysiological 
CAV mechanism which may be different in the early versus late stage after HTx.   
 
3.2.2 Immunological factors 
 
The pathogenesis of CAV development is complex and a host of pathophysiological 
mechanisms are likely to play a contributory role. A range of experimental, animal, clinical 
and epidemiological studies have established that both immunological and non-
immunological factors can be implicated in this process (11-13). A key characteristic of CAV 
is that intimal hyperplasia and inflammatory cell infiltration are limited to the graft 
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vasculature with sparing of the host’s own arteries and this indicates the presence of a 
primarily local inflammatory process. Endothelial cells of the allograft are the first donor cells 
to be recognized as non-self by the recipient’s immune system by either the direct or indirect 
allorecognition pathway. The direct pathway involves identification of donor human 
leukocyte antigen (HLA) molecules by recipient dendritic cells (13, 14). Indirect recognition 
occurs when donor antigens are internalized, processed and presented as peptides by host 
dendritic cells (15) triggering a cellular alloimmune response involving T-lymphocytes and 
macrophages. There is evidence indicating that whereas direct allorecognition is responsible  
for acute rejection, the indirect pathway is likely to be critical for development of CAV (13).  
Recognition of HLA class II antigens on the surface of donor endothelial cells by 
circulating CD4 lymphocytes is a key stimulus for initiation of a cellular response against the 
allograft endothelium (16). This initial event triggers secretion of a range of stimulatory 
cytokines (interleukin [IL]-2, IL-4, IL-5, IL-6, interferon-gamma [IFN-], tumor necrosis 
factor-which in turn induce the expression of endothelial adhesion molecules (intercellular 
adhesion molecule-1, vascular cell adhesion molecule-1). Adhesion molecules mediate the 
recruitment and accumulation of macrophages in the intima leading to a sustained 
inflammatory response where activated cells in the vessel wall produce cytokines and growth 
factors (platelet derived growth factor, insulin like growth factor-1, fibroblast growth factor, 
heparin-binding growth factor and transforming growth factor-stimulating smooth muscle 
cell proliferation and extracellular matrix deposition that characterizes CAV (17). 
 
 
 
Figure 2. Development of cardiac allograft 
vasculopathy (CAV). Histological studies reveal that 
CAV development is characterized by intimal hyperplasia 
with smooth muscle cell proliferation, accumulation of 
inflammatory and lipid-filled cells as well as free lipid 
deposition. (Copyright ©2009 Oslo University Hospital, 
Rikshospitalet. All rights reserved.) 
 
free lipid macrophage T-cell  endothelial cell 
dark smooth muscle cell  smooth muscle cell 
 elastic lamina 
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The humoral alloimmune response may also contribute to the development of CAV as 
it has been shown that circulating anti-HLA antibodies are associated with angiographic CAV 
(18) and adverse survival (19). Furthermore, it has been reported that patients with rapidly 
progressive CAV have elevated IgM antibodies against endothelial cell peptides (20). 
However, the significance of these findings remains unclear as increased antibody formation 
may be a consequence of B-cell proliferation and stimulation as part of the cellular 
alloimmune response.  
 
3.2.3 Non-immunological factors 
 
Numerous studies have investigated the role of non-immunological factors for CAV 
development and it has been reported that older donor age (12), donor gender (12), obesity 
(21), hyperglycemia (22), hypertension (23), hyperhomocysteinemia (24) and 
cytomegalovirus (CMV) infection (25) are independent risk factors. However, other studies 
have reported contradictory results and a further limitation is that most investigators have 
employed angiography to diagnose CAV despite its lack of sensitivity. According to the 
ISHLT registry, risk factors for CAV within 5 years following HTx include: era of HTx, 
donor history of hypertension, donor gender and age and ischemic heart disease as etiology 
for HTx (1). 
Hyperlipidemia and insulin resistance are common metabolic risk factors for 
traditional atherosclerosis and also occur frequently amongst HTx recipients with a reported 
prevalence of 50-80% (26). Hyperlipidemia is often related to the use of calcineurin inhibitors 
whereas hyperglycemia may occur secondary to the use of steroids employed as part of HTx 
immunosuppressive therapy protocols. It has been demonstrated that total cholesterol, low 
density lipoprotein (LDL) and triglyceride levels are independent risk factors for increased 
intimal thickening determined by IVUS (21). Randomized trials have also confirmed that 
statin therapy early after HTx reduces the incidence and severity of CAV development (27). 
Similarly, it has also been shown that insulin resistance and glucose intolerance are strong 
determinants of IVUS determined CAV (22). There is evidence indicating that hyperglycemia 
and hyperlipidemia contribute to CAV development via upregulated expression of adhesion 
molecules on endothelial cells (28) triggering a cellular proliferative response associated with 
CAV. 
Studies have also indicated that viral pathogens, particularly CMV infection, may be 
involved in CAV pathogenesis. For example, it has been shown in observational studies that 
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CMV infected patients had a significantly higher risk of severe coronary artery obstructive 
lesions (29) and this is supported by clinical studies demonstrating a beneficial role of CMV 
therapy on CAV incidence (25). It has been suggested that viral pathogens, such as CMV, can 
influence CAV incidence and progression via a direct effect on proinflammatory cytokine 
induction and expression of adhesion molecules (30) or, secondary to impaired vasodilatation 
of the coronary vasculature due to changes in the endothelial nitric oxide synthase (eNOS) 
pathway (28).   
Endothelial dysfunction refers to abnormal vasoreactivity in response to local 
acetylcholine administration and there are studies indicating that it can be detected early after 
HTx and predicts the development of CAV (31, 32). Several proposed mechanisms may 
mediate endothelial dysfunction, including generation of superoxide anions, increased 
degradation of nitric oxide (NO) or impaired synthesis of NO secondary to increased levels of  
asymmetric dimethylarginine (ADMA) (28). Elevated ADMA levels are associated with 
several traditional risk factors for atherosclerosis, including diabetes, hypertension and renal 
failure. Consequently, endothelial dysfunction may be a common mediating pathway that 
links various non-immunological risk factors to the development of CAV.  
 Overall, it is likely that the development of CAV occurs secondary to a complex 
interplay of both immunological and non-immunological factors which results in endothelial 
activation and a chronic inflammatory response causing intimal hyperplasia due to 
inflammatory cell accumulation, proliferation of vascular smooth muscle cells and deposition 
of an extracellular tissue matrix (Figure 2).  
 
3.3  Diagnosis of cardiac allograft vasculopathy  
 
Due to cardiac denervation at the time of HTx, development of CAV is often clinically silent 
and patients present late with silent myocardial infarction, loss of allograft function, 
arrhythmia or sudden death (33, 34). Identification of CAV is, therefore, an important goal 
and various invasive and non-invasive methods can be utilized in clinical practice.  
 
3.3.1 Invasive methods 
 
3.3.1.1 Coronary angiography 
 
It has been shown that the diagnosis and progression of CAV determined by coronary 
angiography is of prognostic significance (35, 36). Although this is the rationale for annual 
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surveillance angiography of HTx recipients, several studies have demonstrated that this 
technique has significant limitations and low diagnostic sensitivity (37, 38). This is primarily 
attributable to the lack of lumen obstruction in early CAV development secondary to 
compensatory enlargement and vascular remodeling processes (39). Furthermore, the diffuse 
and longitudinal distribution of CAV may also result in the lack of a normal reference 
segment resulting in underestimation of disease prevalence. Hence, although a specific 
diagnostic method, angiography is a relatively insensitive method for CAV diagnosis and 
surveillance.  
 
I. Invasive methods 
 Coronary angiography 
 Intravascular ultrasound 
 Assessment of coronary vasomotor alteration (e.g. by Doppler flow wire) 
 Myocardial biopsy molecular analysis 
- antithrombin-III  
- HLA-DR  
- intercellular adhesion molecule-1  
II. Non-invasive methods 
 Biomarkers 
- Myocyte injury markers (e.g. Troponin) 
- Myocyte stress markers (e.g. BNP or NT-proBNP) 
- Inflammatory markers  
i) CRP 
ii) inflammatory cytokines 
iii) anti-inflammatory cytokines 
iv) chemokines 
- Oxidative stress markers (e.g. TBARS, oxidized LDL) 
- Gene expression markers (e.g.AlloMap)  
 Dobutamine stress echocardiography 
 Multidetector CT  
 Single photon emission CT (SPECT) 
 
Table 2. Invasive and non-invasive methods for detection of cardiac allograft 
vasculopathy. 
 
3.3.1.2 Intravascular ultrasound  
 
Intravascular ultrasound is an advanced imaging modality with an axial resolution of 50-80 
μm (39) that generates detailed cross-sectional images of the coronary lumen and entire 
arterial wall (Figure 3). This allows accurate assessment of intimal wall thickness and vessel 
and lumen dimensions. According to angiographic evaluation CAV is present in <10% of 
HTx recipients at one year post-HTx (1) but IVUS studies indicate that the disease can be 
detected in up to 75% of HTx recipients at the same time point (40). 
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Normal coronary artery intimal thickness has typically been reported to range between 
0.10-0.25 mm (41, 42) and, hence, many investigators consider  CAV as intimal thickness 
>0.3 mm or when the sum of intimal and media thickness exceeds 0.5 mm. Studies have 
employed IVUS to demonstrate that CAV often progresses most rapidly during the first year 
after HTx (3). Such rapidly progressive CAV, defined as an increase in maximum intimal 
thickness (MIT) 0.5 mm, is a powerful predictor of all-cause mortality (43) and patients with 
such intimal thickening are 10 times more likely to experience an adverse cardiac event (44). 
Although a few studies have shown that intimal thickness demonstrated by IVUS correlates 
poorly to small vessel disease detected by histological or immunohistochemical analysis (45), 
this imaging modality remains one of the best available surrogate markers of predicting 
adverse outcomes related to CAV.  
 Despite the diagnostic accuracy of IVUS its use has traditionally been limited to 
research and investigational purposes. This is largely attributable to the financial costs of 
performing IVUS analysis and technical limitations which include the inability to image 
vessels with a diameter <1.5 mm (catheter size is 		



selected coronary artery.  
 
3.3.1.3 Virtual Histology 
 
Virtual histology (VH), developed by Volcano Corporation Inc, Rancho Cordova, California, 
is a relatively new technique where backscatter radiofrequency data obtained during IVUS 
pullback is utilised for qualitative plaque assessment. This technique has been shown to have 
a 94–97% ex-vivo and 87–97% in-vivo accuracy for characterization of four basic tissue 
components (fibrous, fibrofatty, calcified and necrotic core components – Figure 3) amongst 
patients with ischemic heart disease (46, 47). Given our limited understanding of the complex 
in-vivo processes responsible for CAV such an assessment of tissue composition amongst 
HTx recipients represents a novel and potentially valuable tool that is being increasingly 
utilised in prospective trials amongst HTx recipients. 
 
 3.3.1.4 Other invasive methods 
 
Invasive assessment of epicardial and microvascular endothelial function (e.g. by Doppler 
flow wire) may also be helpful in detecting significant CAV (48, 49). However, there are 
conflicting reports (50) regarding the accuracy and utility of this method. Myocardial biopsy 
molecular analysis is another invasive method that may allow early CAV detection and this 
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approach includes assessment of various molecules, including, HLA-DR, intercellular 
adhesion molecule-1 and anti-thrombin III (51-53). However, this technique requires 
methodological improvement and validation before it can be considered in routine clinical 
practice.  
 
 
Figure 3. Left: Example of an IVUS recording allowing accurate visualization of intimal wall 
thickening. Intima and media corresponds to area between the drawn yellow and red contour.  
Right: Example of a Virtual Histology (VH) tissue map generated via analysis of backscatter 
radiofrequency data obtained during IVUS imaging. 
 
 
3.3.2 Non-invasive methods 
 
3.3.2.1 Biochemical markers 
 
Non-invasive detection of CAV by use of simple biomarkers measuring cardiac damage, 
systemic inflammation or endothelial activation remains a focus of active research. It has been 
shown that persistent elevation of troponin I levels during the first year post-HTx is associated 
with an increased risk of CAV progression and graft failure (54). Similarly, elevated C-
reactive protein (CRP), a marker of systemic inflammation is also associated with CAV 
development and graft failure (55, 56). Brain natriuretic peptide (BNP), a neuroendocrinal 
hormone, is likely to reflect ongoing remodeling of the allograft and elevated levels have been 
shown to predict the development of CAV (57). Although the positive predictive value of 
many of these biomarkers is relatively low, they represent relatively cheap and efficient non-
invasive parameters that can be measured in routine clinical practice as part of risk-
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stratification protocols. Combined measurement of different biomarkers may also allow 
increased sensitivity and specificity and needs further investigation.  
Measurement of inflammatory biomarkers may represent a non-invasive method of 
CAV detection and chemokines such as, monocyte chemotactic protein-1 (MCP-1), have been 
shown to be specifically associated with CAV (58). In addition, soluble IL-2 receptor levels 
have been found to be elevated in CAV diagnosed by angiography early after HTx (59). 
Another potential biomarker is oxidized LDL which has been shown to be related to 
angiographic CAV in both retrospective and prospective studies (60, 61). Finally, the 
AlloMap gene-expression test which has previously been shown to detect acute rejection  also 
appears to be associated with CAV (62). Further studies are now being considered to 
investigate the value of this genetic biomarker in predicting the development of CAV.  
 
3.3.2.2 Other non-invasive methods 
 
Recent studies have demonstrated that stress echocardiography can be used as a reliable non-
invasive method for detecting CAV and myocardial ischemia (63). Although there is good 
correlation between the presence of CAV and regional myocardial function, it should be noted 
that the latter is a subjective interpretation resulting in a wide range of reported sensitivities 
and specificities for this method (63-65).  Single-photon emission computed tomography 
(SPECT) and 64-slice multidetector CT imaging are two promising imaging modalities that 
are being explored as an alternative to angiography and there is data indicating these methods 
have moderate to excellent test characteristics for CAV detection (66, 67). However, 
important limitations are spatial resolution, radiation exposure and the potential difficulty in 
obtaining good quality images due to the relatively higher heart rate amongst HTx recipients. 
 
3.4 Treatment of cardiac allograft vasculopathy  
 
Given the adverse prognosis associated with CAV, effective treatment is an important goal of 
post-HTx management. Current strategies largely focus on prevention of CAV by targeting 
immunological factors and treating or modifying non-immunological risk factors associated 
with CAV. Advanced CAV may be amenable to interventional treatment but generally has 
limited prognostic benefits.  
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3.4.1 Targeting the immune system 
 
 Calcineurin inhibitors (CNI), such as cyclosporine (CsA) or tacrolimus, are generally 
considered essential immunosuppressive medication for HTx recipients as they have been 
shown to dramatically reduce the frequency of acute rejection episodes and improve survival 
(68). However, despite the widespread use of these agents, the high prevalence of CAV may 
suggest that such therapy is not effective in preventing CAV development (13, 69). A 
potential explanation is that CAV is mediated via pathways not inhibited by CNIs, such as, 
complement activation (13, 70) or production of antiendothelial antibodies (13, 71). 
Furthermore, long-term use of CNIs is associated with an increased risk of developing 
complications, such as renal dysfunction and hypertension, which may accelerate the 
progression of CAV. Studies have also tried to assess differential effects of CyA versus 
tacrolimus but results are inconsistent. Klaus et al. (72) found that tacrolimus therapy was 
associated with increased CAV progression, whereas Meiser et al. (73) reported a non-
significant trend towards increased CAV amongst patients receiving CyA therapy. 
 
I. Targeting the immune system 
 Immunosuppression therapy 
- Calcineurin inhibitors 
- Mycophenolate mofetil 
- Proliferation signal inhibitors 
 Immunomodulatory treatment 
- 15-deoxyspergualin 
- CTLA-4-Ig  
- interleukin-10 stem cell therapy 
II. Targeting non-immunological factors 
 HMG-CoA inhibitors (statins) 
 Vasodilators 
- ACE inhibitor 
- Calcium channel blocker 
 Endothelial protection 
- L-arginine 
- Antioxidants 
 Anti-CMV therapy (ganciclovir) 
     III. Interventional options 
 Coronary artery bypass grafting (CABG) 
 Percutaneous coronary intervention (PCI) 
 Retransplantation 
 
Table 3. Therapeutic strategies to target cardiac allograft vasculopathy.  
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 Immunosuppressive therapy with CNI is generally complemented with either 
azathioprine (AZA) or mycophenolate mofetil (MMF). The latter inhibits inosine 
monophosphate dehydrogenase which is an essential enzyme required for DNA synthesis by 
lymphocytes. Furthermore, MMF may also exert its effect via inhibition of adhesion molecule 
glycolysation (74) contributing to reduced inflammatory infiltration of the intima. A 
randomized controlled trial has demonstrated that patients treated with MMF had a 35% 
reduction in 3 year mortality or graft loss compared with patients treated with AZA (75). 
Although no significant difference in angiographic CAV was evident in this trial, reanalysis 
of the IVUS data (76) revealed that fewer patients receiving MMF developed intimal 
thickness 		
!-HTx (43% versus 23%, p=0.005). Consequently, 
MMF is increasingly replacing AZA in the immunosuppressive protocol employed at many 
HTx centers.  
Sirolimus and everolimus (synthetic derivative of sirolimus) interfere with interleukin-
1-mediated signal transduction pathways signals and inhibit proliferation of B and T 
lymphocytes, fibroblasts and smooth muscle cells (77, 78). These agents may, therefore, 
inhibit CAV development or progression and represent an attractive replacement for CNI 
therapy (79).  It has been shown that HTx recipients randomized to sirolimus had a lower 
incidence of a composite endpoint of death, need for angioplasty or bypass surgery, 
myocardial infarction or a >25% worsening of the catherization score (80). Everolimus has 
been evaluated in a large trial with over 600 patients that showed reduction of all IVUS 
endpoints in patients treated with everolimus versus azathioprine (81). However, no 
improvement in survival was reported and a worse triglycerides and renal function were 
found in patients receiving everolimus (81). Nevertheless, proliferation signal inhibitors may 
represent a significant advancement of CAV treatment and a recent multidisciplinary report 
concluded that the majority of de novo heart transplant recipients could benefit from 
everolimus therapy (82).  
 Various novel immunomodulatory agents are also being explored in an attempt to 
prevent the development of CAV. These agents include 15-deoxyspergualin which suppresses 
macrophage function and has been investigated in animal models and appear to prevent CAV 
development (83) as well the costimulation signal inhibitor CTLA-4-Ig which has been shown 
to prevention posttransplant arteriopathy in mouse aortic allografts (84). Stimulation of anti-
inflammatory pathways via administration of IL-10–engineered hematopoietic stem cells may 
also prolong allograft survival (85). Such specific agents require further investigation with 
particular attention being given to the role of targeted combination therapy which may allow a 
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coordinated blockage of central immunological mechanisms responsible for CAV 
development.  
 
3.4.2 Targeting non-immunological factors  
 
Hyperlipidemia occurs frequently amongst HTx recipients and has a reported prevalence of 
93% in the first 10 years after HTx (1). This is likely to be attributable to a range of factors, 
including cyclosporine therapy and insulin resistance secondary to steroid treatment. Trials 
have demonstrated that routine therapy with 3-hydroxy-3methylglutaryl coenzyme A (HMG-
CoA) inhibitors, or statins, is associated with a beneficial effect on cardiac allograft rejection 
and survival (27, 86). It has also been shown that this protective effect is evident independent 
of changes in lipid levels and may, therefore, reflect immunomodulatory effects of statin 
therapy such as decreased cytokine activity [interleukin-6 and tumor necrosis factor (TNF)-" 
or improved coronary endothelial function (87). Statins also reduce levels of CRP amongst 
HTx recipients (55) and may inhibit T-lymphocyte activation by interfering with IFN- 
mediated expression of HLA class-II molecules on coronary endothelial cells (88).  
According to the ISHLT registry, 98% of HTx recipients have hypertension 10 years 
after HTx (1). Nephrotoxicity secondary to CNI therapy is an important contributing factor 
(89) and it has been demonstrated that treatment of hypertension early after HTx with calcium 
antagonists reduces CAV development and improves overall survival at 1 year post-HTx (90). 
Similarly, treatment with angiotensin converting enzyme (ACE) inhibitors can delay 
development of CAV (23) via mechanisms that may include improved endothelial 
dysfunction and oxidative stress (13). Furthermore, it has been shown that the combined use 
of an ACE inhibitor and a calcium antagonist is more effective than the individual use of 
either drug alone on CAV development (91). However, further studies are required to validate 
these results.  
Insulin resistance and diabetes are also common comorbidities amongst HTx 
recipients. Although, a strong risk factor for traditional atherosclerosis, their role in CAV 
development is less clear. In one study no increased risk of CAV was evident amongst 
patients with diabetes (92), whereas in another study, hyperglycemia was associated with 
greater intimal thickness during a follow-up period of 8 years (22). Larger prospective studies 
are, therefore, required to evaluate the potential benefit of intensive glycemic control for 
development of CAV amongst HTx recipients.    
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Given the association between endothelial dysfunction and development of CAV, 
studies have focused on investigating whether oral L-arginine (a precursor of NO synthase) 
therapy can reverse endothelial dysfunction (93), buffer increased vascular oxidant stress (94) 
and, hence, influence CAV development. Although the results are promising, the effect of L-
arginine needs to be investigated further in larger randomized, prospective trials. Similarly, 
there is data indicating that supplementation with antioxidants, such as, vitamins C and E (95) 
or riboflavin (96) can limit intimal smooth muscle proliferation and retard the early 
progression of CAV.  
 Infection with CMV is an important complication post-HTx (97) and studies indicate 
that this viral pathogen may contribute to CAV development via dysregulation of the NO 
pathway (98) or cytokine activation resulting in inflammatory cell recruitment associated with 
intimal thickening (99). There is observational data supporting this hypothesis as well as data 
from clinical trials demonstrating that patients randomized to receive prophylactic anti-viral 
therapy with ganciclovir have a lower risk of developing CAV (25).  However, it must also be 
noted that there are other reports concluding that CMV viremia or infection does not affect 
CAV development (100). Traditionally, HTx recipients with the CMV seromatch status 
D+/R- have been considered at highest risk of CMV viremia and an increased risk of CAV 
amongst this group of patients has been shown (101) . However, in a recent study by Hussain 
et al. (102)  it was demonstrated that pretransplant recipient CMV seronegativity is not a risk 
factor for CAV development. Hence, although CMV may represent a culprit that can be 
effectively treated, further trials are required to evaluate whether implementing prophylactic 
CMV therapy as part of post-HTx management protocols can reduce the long-term risk of 
CAV and associated mortality.  
 
3.4.3 Interventional options 
 
There are limited treatment options for advanced CAV. Pharmaceutical therapy has limited 
effect on established CAV and interventional options include retransplantation, coronary 
artery bypass grafting (CABG) or percutaneous coronary intervention (PCI). However, 
retransplantation is generally very difficult due to multiple comorbidities and lack of donor 
organs, while CABG has a high perioperative mortality rate (103). Although PCI is a common 
therapeutic approach for traditional atherosclerosis, the restenosis rate in the setting of CAV is 
particularly high (104, 105). Furthermore, no survival benefit has been demonstrated after 
PCI of HTx recipients (13, 106) and in one study freedom from death or retransplantation 
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following PCI was only 34% at 5 years (104). Consequently, the indication for such 
revascularization interventions should be critically evaluated in all patients. 
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4. AIMS OF THE THESIS 
 
The aims of this thesis were to investigate immunological and non-immunological markers of 
CAV, particularly focusing on: 
 
i) The role of the neurohormonal biomarker, NT-proBNP, and the inflammatory biomarker, 
CRP, in identification of HTx recipients at higher risk of CAV and cardiac mortality 
ii) The prognostic significance of impaired renal function post-HTx and whether any 
particular level of decline during the first year post-HTx is associated with an increased risk 
of CAV and mortality 
iii) The potential adverse impact of chronic infection with the parasite T.gondii amongst HTx 
recipients in relation to CAV and cardiac mortality 
iv) Utilization of IVUS and VH to allow an accurate evaluation of CAV and measurement of 
a broad inflammatory biomarker panel to allow identification of novel disease markers.  
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5. METHODOLOGICAL CONSIDERATIONS 
 
5.1 Patient population 
 
Our institution is the only HTx centre in Norway and all activity regarding preoperative HTx 
evaluation, surgery and postoperative management is undertaken here. All patients included in 
this thesis gave informed consent and are part of cohort of 585 patients that have undergone 
single organ HTx during the period 1983-2007. All studies complied with the Declaration of 
Helsinki and the locally appointed ethics committee approved the research protocol. The 
annual number of single organ HTx procedures performed at our centre generally ranges 
between 25 and 40 and the indication for HTx is in accordance with international guidelines.  
All HTx recipients were evaluated for acute rejection via endomyocardial biopsies 
performed upon clinical suspicion and at the following intervals: weekly the first 2 months 
after HTx, fortnightly in the third month and then after 6, 12, 24 and 36 months. A standard 
immunosuppressive protocol is applied consisting of maintenance therapy with CsA or 
tacrolimus, prednisolone and AZA or MMF (the latter replaced AZA from 2002 onwards). No 
cytotoxic induction therapy is used and statin therapy was implemented as protocol from 1997 
onwards.  
All patients attended annual follow-up visits which includes a clinical assessment, 
biochemical profiling and coronary angiography unless contraindicated. A standardized 
regime of immunosuppressive medication, rejection surveillance and annual angiography was 
employed and allowed accurate comparison of patient outcome. Patients included in this 
thesis were included at the time of HTx (Papers I and III) or at an annual follow-up visit 
(papers II and IV).  
 
5.2 Measurement of biomarkers 
 
All biomarkers evaluated in thesis were measured in plasma samples obtained by standard 
venepuncture. Samples were stored on ice in tubes containing EDTA which is the preferred 
anticoagulant for immunoassays as it appears to inhibit ex-vivo production of pro-
inflammatory substances (107, 108). Samples were centrifuged within 30 minutes of 
collection and stored at -80°C as such a standardized processing and storage procedure limits 
the effect on assay measurements (109, 110). Samples were subsequently thawed at room 
temperature but repeated freeze-thaw cycles were avoided as this can also influence 
biomarker measurements (110).  
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5.2.1 C-reactive protein 
 
CRP is an inflammatory marker primarily synthesized by hepatocytes in response to IL-6 with 
synergistic enhancement of IL-1 or tumor necrosis factor (TNF) (111). There appears to be a 
strong relationship between traditional atherosclerosis and high sensitivity (hs) CRP and it is 
gaining acceptance as a tool for cardiovascular disease risk assessment (112). In this thesis, 
CRP was measured on a Roche Modular analyzer using the Tina-quant hs-CRP (Latex) HS 
assay (Roche Diagnostics, Indianapolis, Ind.). Given that CRP is an acute phase reactant we 
ensured that all patients were free from any acute clinical infection at the time of sampling to 
avoid erroneous results. This high-sensitivity assay is based on anti-CRP antibodies coupled 
to latex microparticles that react with sample antigen to form an antigen/antibody complex 
which is measured turbidmetrically (particle enhanced immunoturbidmetric assay) (113). In 
our laboratory the interassay variance was <10% in the range 0.1-300 mg/L.  
 
5.2.2 N-terminal probrain natriuretic peptide 
 
Brain natriuretic peptide (BNP) is a 32 amino acid cardiac natriuretic peptide hormone 
originally isolated from porcine brain tissue (114). It is released into the circulation in 
response to volume overload, ventricular stretching and hypertrophy and regulates natriuresis, 
vasodilatation, inhibition of renin and aldosterone production and of cardiac and vascular 
myocyte growth. This neurohormone is synthesized in ventricular cardiomyocytes as larger 
molecules (proBNP) that are subsequently cleaved prior to secretion to yield the active 
peptide hormone (BNP) and the biologically inactive N-terminal peptide fragment (NT-
proBNP) (114). In comparison to BNP, NT-proBNP degrades more slowly both in-vivo and 
ex-vivo, has a higher circulating concentration, and is more stable, with less biological 
variability (115).  
 We measured NT-proBNP using an electrochemiluminescence immunoassay which 
uses the sandwich principle (Roche proBNP, Roche Diagnostics, Basel, Switzerland). In the 
first incubation, sample antibody, biotinylated polyclonal NT-proBNP-specific (amino acids 
1–21) antibody and polyclonal NT-proBNP-specific (amino acids 39–50) antibody labeled 
with a ruthenium complex form a sandwich complex (116). In the second incubation, after 
addition of streptavidin labeled microparticles, the complex produced is bound to the solid 
phase via biotin-streptavidin interaction. The reaction mixture is aspirated into the measuring 
cell where microparticles are magnetically captured on an electrode and subsequent 
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application of a voltage induces a chemiluminescent emission which is measured by a 
photomultiplier. Results are determined via a calibration curve. In our laboratory the lower 
detection limit was 0.6 pmol/L and the coefficients of variation were 4.5% and 2.5% in low 
and high ranges of NT-proBNP.  
 
5.2.3 Renal function 
 
Renal impairment is associated with an increased risk of mortality in chronic heart failure 
patients (117-119) and although there is data suggesting that this also applies to HTx 
recipients (120, 121), the relationship to development of CAV is not clear. In this thesis renal 
function was assessed by calculating estimated GFR according to the established Modification 
of Diet in Renal Disease Study (MDRD) formula that has been used in several large clinical 
trials and has also been shown to be accurate in HTx recipients (122-124). According to this 
formula, estimated GFR=186 x serum creatinine-1.154 x Age-0.203 (x 0.742 if female and x 0.210 
if African-American). Estimated GFR was calculated and categorized according to National 
Kidney Foundation Disease Outcomes Quality Initiative (NKF-K/DOQI) Guidelines which 
classify GFR <30 ml/min/1.73 m2 as severe GFR reduction and GFR between 30 and 59 
ml/min/1.73 m2 as moderate reduction (125).  
 
5.2.4 Enzyme Linked Immunosorbent Assays (ELISAs) 
 
The Enzyme Linked Immunosorbent Assay (ELISA) is a highly versatile and sensitive 
technique that can be used for qualitative or quantitative determination of antibodies or 
antigen (126). Cytokines are generally measured by sandwich ELISAs which makes use of 
highly purified anti-cytokine antibodies (capture antibodies) which are non-covalently 
absorbed (“coated” – primarily as a result of hydrophobic interaction) onto plastic microwell 
plates. The immobilized antibodies serve to specifically capture cytokine proteins present in 
plasma samples applied to the plate. After washing away unbound material, a biotin-
conjugated detection antibody is added which binds to the captured cytokine antigen. 
Subsequently, an enzyme conjugated to avidin/streptavidin is added and this binds to the 
antigen-antibody sandwich (by exploiting the natural high affinity between avidin/streptavidin 
and biotin). Finally, a substrate solution (e.g. tatramethlybenzidine/hydrogen peroxide) is 
added and leads to development of a colored product that is proportional to the cytokine 
assessed and can be measured spectrophotometrically. 
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We measured plasma levels of soluble tumor necrosis factor receptor-1 (sTNFR-1), 
IL-6, osteoprotegerin (OPG), soluble gp130 and vascular cell adhesion molecule 1 (VCAM-1) 
by sandwich ELISAs obtained from R&D Systems (Minneapolis, MN). Plasma levels of 
neopterin and von Willebrand factor (vWf) were measured by ELISAs provided by Brahms 
(Henninsdorf, Germany) and DakoCytomation (Oslo, Norway), respectively. Analysis was 
performed according to the manufacturers’ specifications and all intra-assay and inter-assay 
coefficients of variance were <10%.  
Sandwich ELISAs are very useful for cytokine detection and measurement but several 
limitations regarding data interpretation must be mentioned. As in the case of this thesis, 
cytokine concentrations are often measured at a single time point and these results do not 
reflect the concurrent processes of cytokine secretion, uptake by cells and cytokine protein 
degradation. Also, the presence of soluble cytokine receptors, cytokine antibodies and binding 
protein may affect the measured cytokine concentrations (127). Hence, ELISAs do not 
provide any information regarding the biological in-vivo potency of the measured proteins. 
Another important limitation is the unique recognition profile of the antibodies between kits 
from different manufacturers and this makes absolute comparison of cytokine concentrations 
unreliable. There is also a considerable potential for run to run variability, although this was 
minimized in this thesis by performing each cytokine analysis for all included subjects on the 
same day.    
 
 
 
 
 
Figure 4. Principles of sandwich ELISA. (1) Plate is coated with a capture antibody; (2) sample is 
added, and any antigen present binds to capture antibody; (3) detecting antibody is added, and binds to 
antigen; (4) enzyme-linked secondary antibody is added, and binds to detecting antibody; (5) substrate 
is added, and is converted by the enzyme to a detectable form.  
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5.2.5 Toxoplasma gondii immunoglobulin analysis 
 
The diagnosis of toxoplasmosis, a zoonosis caused by the protozoan Toxoplasma gondii, is 
based on serological tests which detect immunoglobulin M (IgM) and IgG antibodies. In 
recent years, several commercial diagnostic kits have been developed allowing automated 
detection of antibodies to T gondii based on ELISA) technology (128). In this thesis, recipient 
and donor IgG T.gondii serostatus were determined by an established IgG (Platelia Toxo IgG 
TMB, Bio-Rad, Marnes-la-Coquette, France) with the same lot number to ensure diagnostic 
accuracy.  
The Platelia IgG assay is an indirect ELISA where diluted test samples are placed in 
T.gondii antigen coated microplate wells forming anigen-antibody complexes. Unbound 
antibodies and other serum proteins are removed by washing. Subsequently, peroxidase-
labeled monoclonal antibody specific for human IgG is added and this binds to antigen-
antibody complexes attached to the microplate wells. Following a second washing cycle, a 
solution of peroxidase substrate and chromogen tetramethylbenzidine (TMB) is added 
initiating a color reaction. The enzymatic reaction, read as optical density on a 
spectrophotometer, is proportional to the quantity of T.gondii IgG antibody present in the test 
sample. The qualitative results are calculated using a standard curve and expressed in 
international units/ml (IU/ml). We classified an optical density reading > 6.0 IU/ml as 
T.gondii seropositive, according to the manufacturer’s instructions and previously published 
data (129).  
 
           
 
 
 
 
 
 
 
 
Figure 5. Schematic representation of Toxoplasma 
gondii parasite. Prior infection by T.gondii can be 
determined using indirect enzyme immunoassays such as 
the Platelia Toxo IgG assay. 
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5.3 Definition of endpoints 
 
5.3.1 Mortality 
 
Mortality data for all patients included in the thesis was available from the Norwegian 
Population Register. This national registry also includes causes of death allowing accurate 
data analysis and complete follow-up of included patients.  
 
5.3.2 Diagnosis of cardiac allograft vasculopathy 
 
5.3.2.1 Angiography 
 
All patients included in the thesis underwent annual angiographic surveillance unless 
clinically contraindicated. The classification system applied by Costanzo et al. (130) was used 
to grade CAV as mild, moderate, or severe on the basis of left main involvement, primary 
vessel stenoses, and branch stenoses. Disease was considered as severe if left main stenosis 
was > 70% or 2 or more primary vessels stenoses were > 70% or branch stenoses were > 70% 
in all 3 systems. Angiographic films for all included patients were available for reanalysis if 
required. Despite the technical limitations of CAV detection by angiography, utilization of 
such a standardized grading system allowed a more accurate comparison of disease severity 
amongst the patients included in the thesis.  
 
5.3.2.2 Intravascular ultrasound and Virtual Histology 
 
The sensitivity of IVUS analysis in comparison to angiography for CAV detection is well-
established. All patients included in Paper IV were evaluated with IVUS to allow such an 
accurate quantative assessment of CAV. In addition, Virtual Histology was utilized to allow 
qualitative assessment of these lesions. Formal training in IVUS measurements was provided 
by an external internationally renowned laboratory (See Appendix 1: Certificate of IVUS 
training).   
IVUS acquisition. IVUS imaging utilizes a high frequency (30-40 MHz) ultrasound 
transducer on a catheter tip that is placed within the coronary arteries using standard 
angiographic techniques. The transducer generates high-resolution cross-sectional images of 
the coronary lumen and entire arterial wall that permit accurate measurement of dimensions of 
the lumen and vessel wall.  
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In our study, a major coronary epicardial artery (preferentially the left-anterior 
descending coronary artery) was imaged using a 20 MHz, 2.9F, monorail electronic Eagle 
Eye Gold IVUS imaging catheter (Volcano Therapeutics Inc, Rancho Cordova, California) 
and a dedicated IVUS scanner (Volcano Therapeutics). IVUS examination was performed 
after routine angiography following intracoronary administration of 200 μg nitroglycerin. The 
catheter was placed as distal as possible and automated mechanical pullback was performed 
from this start point to the ostium. Images were acquired at a rate of 30 frames/second and a 
pullback speed of 0.5 mm/second resulting in 1 mm intervals between every 60 frames. IVUS 
images were stored on a CD-ROM for later offline 3D volumetric analysis.  
IVUS measurements. Semi-automated detection of both the lumen contour (LC) and external 
elastic membrane (EEM) was performed at intervals of 60 frames using dedicated software 
(QIVUS Clinical Edition, Medis Medical Imaging, Leiden, Netherlands). The longest possible 
segment between the most distal and proximal side branch visualized in the IVUS pullback 
was analyzed for each patient. Following automatic contour detection, borders were edited 
manually by two independent operators according to the guidelines for acquisition and 
analysis of IVUS images by the American College of Cardiology and European Society of 
Cardiology (131) – Figure 6. 
The following parameters were recorded for all patients using the mean result of all 
frames analyzed: (1) lumen cross-sectional area (CSA), (2) vessel CSA, (3) intimal CSA and 
(4) maximal intimal thickness (MIT). In accordance to established guidelines, the largest 
distance from the intimal leading edge to the EEM was defined as MIT (131) and advanced 
CAV was defined as MIT >0.5 mm as this has been shown to accurately predict subsequent 
mortality and non-fatal major adverse cardiac events related to CAV (132). The CSA 
measurements were utilized to calculate Total Atheroma Volume (TAV) using Simpson's 
method as well as Percent Atheroma Volume (PAV) which expresses the summation of 
atheroma areas in proportion to the EEM area using the equation: PAV = #$**?area – 
Lumenarea)/#**?area) x 100. Recent studies suggest that PAV has the smallest coefficient of 
variability (133, 134) and we, therefore, considered this as an additional endpoint for CAV. 
Since there is no established PAV value defining advanced CAV, we pre-specified PAV 
above the mean value as indicative of advanced CAV. In our IVUS laboratory the intra-
observer variability for both CAV endpoints (MIT and PAV) was <3%, whereas the inter-
observer variability was <5% and this is comparable to other centres (133).  
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Figure 6. Example of tracing of contours following intravascular ultrasound (IVUS) acquisition. 
A longitudinal segment of an IVUS recording obtained by the Volcano scanner (left) and an example 
of a transverse IVUS frame (right) manually edited after semi-automated contour detection.  Red 
marking = lumen contour (LC), green marking = external elastic membrane (EEM), blue line = level 
for the transverse image, MIT = maximal intimal thickness.  
 
Virtual Histology. IVUS measurements were performed prior to VH analysis and the same 
segment length and portion that was utilized for CAV quantification (QIVUS software) was 
utilized for qualitative assessment by dedicated VH software (pcVH, v.2.2, Volcano 
Corporation). This required initial semi-automated contour detection of all acquired frames 
captured at the top of the R-wave of the heart cycle. Followed manual editing of contours, 
stored radiofrequency data was utilized by the software to reconstruct tissue maps with four 
identifiable major components – fibrous, fibrofatty, calcified and necrotic core components – 
which were allocated a separate colour coding in digitized images. 
Necrotic core component is composed of lipid cells, necrotic and lymphocyte 
remnants together with tissue microcalcification. Consequently, several previous studies have 
considered necrotic and dense calcified tissue as one group that is likely to constitute the 
inflammatory tissue component of CAV (135, 136). In our study we defined an increased 
inflammatory tissue component as necrotic and dense calcified tissue >30%. This arbitrary 
cut-off has been utilized in another recent HTx study (136) and is supported by the results of 
other in-vivo and ex-vivo VH-IVUS studies performed amongst  patients with IHD (137-140).  
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6. SUMMARY OF RESULTS 
 
Paper I: Probrain natriuretic peptide and C-reactive protein as markers of acute 
rejection, allograft vasculopathy, and mortality in heart transplantation 
 
In this paper we investigated the individual and combined value of NT-proBNP and CRP as 
markers of acute rejection, CAV and all-cause mortality in HTx recipients 
 
 The biomarkers NT-proBNP and CRP are not useful as markers of acute rejection 
after HTx  
 Both biomarkers measured at 12 months or more after HTx are independent predictors 
of all-cause mortality  
 Combined measurement of both biomarkers significantly increases their predictive 
value for all-cause mortality 
 The increased risk of mortality amongst patients with both elevated biomarkers is 
predominantly attributable to a higher risk of cardiovascular death 
 Individual measurement of NT-proBNP and CRP does not predict the development of 
angiographic CAV but patients with both elevated biomarkers have a twofold 
increased risk of developing CAV  
 
Paper II: Prognostic importance of renal function 1 year after heart transplantation for 
all-cause and cardiac mortality and development of allograft vasculopathy 
 
In this study we assessed the relationship between renal function at 1 year post-HTx and all-
cause and cardiac mortality and development of CAV 
 
 A significant majority of patients have impaired renal function at one year post-HTx 
and this is an independent determinant of all-cause and cardiac mortality 
 Impaired renal function at one year post-HTx is not associated with an increased risk 
of development of angiographic CAV  
 Impaired renal function prior to HTx is not a risk factor for mortality or CAV but a 
significant proportion of patients experience a steep GFR decline (>25 ml/min/m2) 
during the first year post-HTx and this is associated with a higher risk of all-cause and 
cardiac mortality.  
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Paper III: Pre-transplant Toxoplasma gondii seropositivity among heart transplant 
recipients is associated with an increased risk of all-cause and cardiac mortality 
 
In this paper we investigated the risk of mortality, CAV and acute cellular rejection among 
T.gondii seropositive HTx recipients and the 4 donor/recipient seropairing groups 
 
 Recipient T.gondii seropositivity is associated with a significantly higher risk of all-
cause and CAV mortality 
 The increased risk of mortality is primarily evident in the period beyond 4 years after 
HTx 
  An increased risk of developing advanced angiographic CAV is demonstrable 
amongst T.gondii seropositive recipients  
 T.gondii seropositivity does not influence the number of acute cellular rejection 
episodes and donor/recipient T.gondii seropairing status is not associated with an 
adverse outcome. 
 
Paper IV: General and specific markers of inflammation are associated with advanced 
cardiac allograft vasculopathy and an increased inflammatory tissue component 
determined by virtual histology analysis 
 
In this study we evaluated an extensive profile of clinical variables and immune markers to 
assess the chronic inflammatory milieu associated with advanced CAV assessed by IVUS and 
intimal inflammatory tissue determined by VH. 
 
 Elevated levels of CRP, VCAM-1 and neopterin are associated with advanced CAV as 
defined by the two separate IVUS endpoints, MIT and PAV  
 Elevated levels of CRP and VCAM-1 are also associated with an increased 
inflammatory component determined by VH analysis 
 The above biomarkers indicate a pathophysiological role of inflammation, particularly 
characterized by endothelial cell and macrophage activation, in the development of 
advanced CAV and potentially vulnerable lesions. 
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7. DISCUSSION 
 
7.1 C-reactive protein and N-terminal probrain natriuretic peptide  
 
C-reactive protein, a pentameric protein produced by hepatocytes under the influence of 
inflammatory cytokines, is an established marker of systemic inflammation. Numerous 
studies have established that CRP provides prognostic information in patients with native 
atherosclerosis (141-144). Given the central role of immune mediated pathways in CAV 
development, CRP may allow accurate measurement of chronic inflammation in HTx 
recipients and, hence, may represent a non-invasive marker of CAV.  
It has previously been demonstrated in a cross-sectional study that increased CRP 
levels are associated with CAV (55) and may also be related to disease progression (145). 
Eisenberg et al. (56) demonstrated that elevated CRP levels were associated with subsequent 
allograft failure in 99 HTx recipients that were included at varying times after HTx. In Paper I 
we evaluated the prognostic value of measurement of this biomarker amongst 210 HTx 
recipients at one year after HTx to predict the development of both advanced CAV and 
mortality. Our results indicate that elevated levels at one year post-HTx are not independent 
predictors of CAV but are associated with an increased risk of mortality that is predominantly 
attributable to CAV. The significant diagnostic limitation of angiography and the associated 
possibility of a type II error is likely to explain the negative finding regarding development of 
CAV. Nevertheless, our positive finding regarding the robust endpoint of mortality supports 
the hypothesis that chronic inflammation plays an important role in development of CAV and 
influences long-term survival. Furthermore, as discussed below, we proceeded to demonstrate 
for the first time that the prognostic information offered by this biomarker can be increased 
significantly when applied in combination with alternative biomarkers.   
  The neurohormone, NT-proBNP, is cleavage product of BNP that is secreted by 
ventricular cardiomyocytes and prior investigations have identified this biomarker as an 
independent predictor of mortality or cardiovascular events in patients with native 
atherosclerosis. Mehra et al. (57)have previously shown that NT-proBNP is also a useful 
marker of CAV. There are several potential explanations for this association including: (i) 
CAV can result in myocardial ischemia and increased ventricular wall stress which may in 
turn be a stimulus for release of NT-proBNP (146) or (ii) BNP release is directly influenced 
by cardiac ischemia (147). Furthermore, along with myocardial stretch and ischemia a range 
of other factors can stimulate BNP secretion, including, endothelin A (148), angiotensin II 
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(148) and TNF-(149) which may also play a pathogenic role in CAV development. 
Consequently, the interdependence of NT-proBNP with local and circulating inflammatory 
factors may allow it to serve as a biomarker for identification of patients at higher risk of 
developing CAV.  
 We evaluated the predictive value of NT-proBNP for CAV and mortality amongst 210 
HTx recipients. We chose to measure this biomarker at one year after HTx as it has been 
shown that levels of this neurohormone fall rapidly during the first few months after HTx but 
tend to stabilize by this point in time (150, 151). However, we did not find that NT-proBNP at 
one year after HTx was an independent predictor of CAV and this may be related to the 
dynamic and variable timescale associated with CAV development and progression. Hence, 
measurement of NT-proBNP at a single time point may not be sufficiently reliable to detect 
the current and impending pathophysiological processes driving CAV. An alternative 
explanation is the possibility of a type II error related to the limitations of angiography. 
Similar to our CRP findings, NT-proBNP was found to be an independent predictor of all-
cause mortality with a negative predictive value of 90% but a positive predictive value limited 
to 28%. 
  Our study found that the combined measurement of CRP and NT-proBNP was an 
independent predictor of both CAV and all-cause mortality. Patients with both elevated 
biomarkers had a two-fold risk of CAV and three-fold risk of mortality. Furthermore, amongst 
patients with elevated CRP, the presence of elevated NT-proBNP clearly identified a group of 
patients at higher risk of adverse outcomes. Our results indicate that CRP and NT-proBNP are 
indicators of two distinct, but potentially overlapping, altered immunological and hormonal 
milieus associated with CAV and increased mortality. Hence, the inherent properties of these 
two biomarkers allow a more accurate reflection of the complex and multi-faceted 
pathological processes responsible for CAV. Although the positive predictive value of 
combined biomarker analysis was limited, the negative predictive value of 70% and 89% for 
CAV and all-cause mortality, respectively, indicates that these biomarkers can be useful 
“rule-out” tests and can assist risk stratification of HTx recipients. Although speculative, 
serial measurement of these biomarkers may yield further prognostic information and herald 
more individualized patient management with more aggressive surveillance and treatment of 
patients at highest risk of developing CAV. 
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7.2 Renal function  
 
It has been established that impaired renal function is a risk factor for cardiovascular mortality 
in the general population (152-154). For example, the mortality due to cardiovascular causes 
is 500-fold greater in patients with end-stage renal failure (155) and this elevated risk is also 
evident in patients with mild renal impairment (153). Although renal impairment is a common 
complication after HTx, its contribution to CAV is not clear. Hence, in Paper II we evaluated 
the prognostic importance of renal function at 1 year after HTx for all-cause and cardiac 
mortality and development of CAV.   
Our study revealed that impaired renal function, as assessed by glomerular filtration 
rate (GFR), at one year post-HTx is a strong predictor of both all-cause mortality and cardiac 
mortality defined as death due to CAV or sudden cardiac death. This risk increased 
progressively with increasing severity of renal impairment with a nearly two-fold increased 
risk of all-cause mortality for patients with moderate renal impairment (GFR 30-60 
ml/min/1.73 m2) and three-fold increased risk in patients with severe renal impairment (GFR 
<30 ml/min/1.73 m2). Furthermore, a steep decline in renal function during the first year post-
HTx is associated with an adverse prognosis. We were unable to demonstrate that impaired 
renal function at one year post-HTx predicted a higher risk of developing CAV and this is 
likely to be related to the technical limitations of angiography. In addition, our study did not 
assess the angiographic progression of CAV. A more rapid progression of CAV may occur 
amongst patients with impaired renal function at one year post-HTx, potentially explaining 
the increased risk of CAV mortality observed amongst this group of patients.  
Multiple lines of evidence have identified exposure to CNIs as a major contributing 
cause to renal dysfunction amongst HTx recipients (156, 157). The renal histopathological 
changes causes by cyclosporine consist of arteriolopathy, glomerulosclerosis, interstitial 
fibrosis and tubular atrophy (158). These changes also contribute to the development of 
hypertension which is a common comorbidity amongst patients with impaired renal function. 
However, although hypertension is a known risk factor for atherosclerosis and may also 
contribute to CAV development (159), there are several other potential pathways that may 
explain the observed relationship between impaired renal function and cardiac mortality 
amongst HTx recipients and are discussed below.   
 It has been demonstrated that patients with impaired renal function have elevated 
serum levels of inflammatory markers such as C-reactive protein and interleukin-6 and tumor 
necrosis factor- (160, 161), indicating potential mechanisms by which renal impairment may 
40 
 
accelerate the chronic inflammatory process associated with CAV development. Furthermore, 
the adhesion molecules E-selectin, VCAM-1 and intercellular adhesion molecule (ICAM)-1 
are elevated in renal impairment (162) and are also believed to mitigate cellular infiltration 
and intimal thickening characteristic of CAV. Another mechanism may involve the renin-
angiotensin system which is known to be activated by multiple pathways in renal disease. It 
has been shown that angiotensin II stimulates NAD(P)H oxidase and leads to generation of 
superoxide anions contributing to endothelial dysfunction (163) and upregulatation of a host of 
inflammatory mediators including cytokines, chemokines, adhesion molecules, and 
plasminogen activator inhibitor-1 (164-166). These events may promote proliferation and 
migration of smooth muscle cells and macrophages causing intimal thickening and 
progression of CAV in HTx recipients with renal impairment.  Finally, plasma concentrations 
of ADMA are often elevated in renal impairment secondary to both increased activity of 
protein arginine methyltransferase and decreased metabolism by dimethylarginine 
dimethylaminohydrolase (167) and infusion with ADMA has been shown to directly induce 
intimal hyperplasia (162). Hence, renal impairment and elevated ADMA levels in HTx 
recipients may directly, or indirectly via their role in triggering endothelial dysfunction, 
contribute to development of CAV.   
The observed relationship between impaired renal function at one year post-HTx and 
all-cause and cardiac mortality strongly indicates the importance of implementing strategies to 
preserve and improve renal function post-HTx. Aggressive monitoring and effective treatment 
of comorbidities that may worsen renal function, such as hypertension and diabetes, is 
essential. Equal attention also needs to be given to renal-sparing immunosuppressive regimes, 
and novel therapies, such as everolimus, that have been shown to improve renal function by 
more than 50% (168) may contribute to a reduction in morbidity and mortality attributable to 
CAV.  
 
7.3 Toxoplasma gondii seropositivity  
 
Toxoplasma gondii is an obligate intracellular parasite and primary infection is largely 
asymptomatic in healthy individuals (169). However, following primary infection, parasites 
are sequestered in various organs throughout the body and latency is maintained by an 
essential adaptive immune response. In Paper III we hypothesized that the chronic 
inflammatory response required to maintain T.gondii latency amongst HTx recipients may be 
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associated with an adverse prognosis and evaluated the relationship between pre-transplant 
T.gondii seropositivity and CAV and cardiac mortality.  
Our study found the pre-transplant T.gondii seropositivity is a risk factor for all-cause 
and CAV mortality and development of advanced CAV. There was a three-fold risk of 
developing advanced CAV and a four-fold risk of mortality attributable to CAV amongst 
seropositive HTx recipients. Our data did not indicate that donor/recipient T.gondii 
seromismatch was a risk factor for any endpoint. Although our study was observational in 
design and did not measure specific markers of immune activity, data was collected on large 
number of covariates and appropriate adjustment was performed in the statistical analysis 
reducing the possibility of spurious results secondary to confounding. Furthermore, the 
immunological response associated with chronic T.gondii infection has been studied in detail 
previously and there are several plausible biological mechanisms (discussed below) that may 
explain our observation of an increased risk of CAV amongst seropositive HTx recipients.  
 It has been established that generation of IFN-@

!XY4 and CD8 
lymphocytes is central to maintaining T.gondii latency (170, 171). The cytokine IL-12 has 
been identified as critical for driving prompt INF- production and proper differentiation of T 
helper (Th) 1 lymphocytes during the immune response to T.gondii (172, 173). With 
relevance to these findings, it is noteworthy that separate studies have also demonstrated IFN-
 as a key mediator of CAV development (174, 175). In addition, there are investigations 
	


@\-IFN suppression and prevention of CAV (176). Hence, 
we suggest that in the HTx recipient, production of IFN- in response to chronic T.gondii 
infection may play an overall detrimental role by promoting an extensive inflammatory 
response involving the intima of coronary arteries and development of CAV. An alternative 
explanation may involve a subset of T-lymphocytes known as TH17 which may be induced by 
T.gondii parasites via mechanisms involving transforming growth factor-and IL-6 (177) . 
TH17 cells produce a range of pro-inflammatory cytokines, including IL-6, TNF, IL-17 (178), 
and this cell lineage is now known to be a major pathogenic mediator of organ-specific 
autoimmune diseases, including rheumatoid arthritis and inflammatory bowel disease  (179) 
and may also be associated with reduced graft survival (180). Hence, although speculative, 
the innate response to T.gondii may induce differentiation of TH17 cells and secretion of a 
range of inflammatory cytokines which promote development of CAV in seropositive HTx 
recipients.   
Our report of T.gondii seropositivity and CAV is a novel finding but the role of other 
microbial pathogens such as, Hepatitis, CMV and EBV, has been studied by several other 
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researchers. CMV has probably received the greatest attention and both observational and 
interventional studies have implicated this viral pathogen in CAV development (25, 181, 
182). For example, it has been shown that CMV-negative recipients from CMV-positive 
donors (D+/R-) are at a high risk of developing CAV (182, 183). We did not find an increased 
risk of CAV amongst T.gondii D+/R- patients and this may be indirectly attributable to the 
relative low risk of T.gondii transmission via the allograft in the era of universal trimethoprim 
sulfamethoxazole prophylaxis and this is supported by our finding of only 1 case of T.gondii 
seroconversion after HTx. Hence, although studies have shown that acute CMV infection and 
the subsequent inflammatory response involving endothelial injury are likely to contribute to 
CAV development (181, 184, 185), our results indicate that acute T.gondii infection is rarely 
encountered in HTx recipients and would not be a significant contributing factor. Another 
evident difference between the two pathogens is that endothelial cells are an important site of 
CMV infection  and CMV has been shown to contribute directly to CAV via a direct pro-
proliferative effect on intimal smooth muscle cells (181), but there is no known data 
supporting or indicating such a direct role of T.gondii parasites on the allograft vasculature. 
However, despite these differences, both pathogens may also share several pathological 
mechanisms as it has been demonstrated that CMV can remain latent and cause chronic 
inflammation in HTx recipients. For example, it has been suggested that allograft endothelial 
cells harbor low-levels of CMV and are capable of directly eliciting host CD4+ T cell 
activation and subsequent release of IFN- (186) . Furthermore, upregulation of the cytokines 
TNF-^_`-6, TGF-
!
\
 (PDGF) may also occur in 
conjunction with low-grade CMV infection (181). Hence, although CMV and T.gondii are 
inherently different pathogens, both microbes can contribute to a pro-atherogenic 
inflammatory environment in HTx recipients which favors the development of CAV.   
 
7.4. Inflammatory markers  
 
There is increasing evidence indicating that multiple inflammatory pathways contribute to the 
development of CAV (4, 28, 187). Histopathological studies have demonstrated focal 
inflammation of the coronary vasculature of HTx recipients (188) and elevation of systemic 
inflammatory markers is associated with an increased risk for CAV and an adverse outcome 
(55, 145). However, no studies have evaluated a broad spectrum of general and specific 
markers of inflammation and their correlation to quantitative and qualitative CAV assessment. 
Such an approach may allow identification of non-invasive markers of CAV and also increase 
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our understanding of the inflammatory mediators and pathways contributing to CAV 
development. Hence, in paper IV we evaluated an extensive panel of immune markers in an 
attempt to assess the inflammatory milieu associated with CAV assessed by IVUS and VH 
intimal tissue analysis. 
Our study concluded that advanced CAV (MIT >0.5 mm) is associated with increased 
levels of CRP, VCAM-1 and neopterin. The two former markers were also found to be 
associated with an increased proportion of inflammatory tissue in the thickened intimal area 
evaluated by VH analysis. Hence, our data indicates a pathophysiological role of 
inflammation that is particularly characterized by endothelial cell and monocyte/macrophage 
activation. We did not find an association between advanced CAV (determined by IVUS or 
VH) and the other assessed markers of inflammation that included sTNFR-1, IL-6, OPG, 
soluble gp130 and vWf. 
CRP is a systemic inflammatory marker that accurately reflects overall cytokine 
activity (189) and its prognostic value amongst HTx recipients has been demonstrated in 
several studies (55, 145). Although CRP may have a direct pathophysiological role in CAV 
(mediated via its prothrombotic effect) it also reflects activation of several upstream 
inflammatory pathways. The present study has confirmed that elevated CRP is strongly 
associated with advanced CAV as measured by two different IVUS endpoints (MIT and 
PAV), and in addition we show a clear relationship between CRP and inflammatory tissue 
content. This intimal characteristic is regarded as an inherently vulnerable tissue type due to 
increased inflammatory cells, higher lipid content, many necrotic cells and foam cells and a 
poor cellular matrix with a higher risk of thrombosis or rupture (190). Consequently, our 
results suggest that the systemic marker CRP can be utilized amongst HTx recipients to 
provide both quantitative and qualitatively information regarding CAV development and 
lesion susceptibility. Precise identification of intimal composition in HTx recipients in this 
manner is vital to allow implementation of a more appropriate risk stratification and 
individualized management protocol that can reduce the current morbidity and mortality 
attributable to CAV.  
A key histological characteristic of CAV development and progression is neointimal 
proliferation and infiltration by macrophages. Initiation of inflammatory pathways resulting 
on activation of T-cells and release of IFN- causing macrophage activation and production of 
growth factors, such as, platelet-derived growth factor (191) and insulin-like growth factor-1 
(192), can contribute to the proliferation of neointimal cells. Neopterin is a reliable marker of 
monocyte/macrophage activation and also reflects the IFN- mediated activation of these cells 
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(193). Our cross-sectional study has demonstrated that elevated plasma levels of this 
inflammatory biomarker are associated with quantitatively advanced CAV but its utility as a 
marker of disease severity and progression requires further investigation in longitudinal 
studies. Similarly, the specific triggers for macrophage activation in HTx recipients and 
development of advanced CAV needs to be explored as it may, ultimately, yield novel 
therapeutic targets. 
The intimal thickening of CAV is characterized by a cellular infiltrate consisting of 
modified smooth muscle cells, macrophages-monocytes and T lymphocytes. Several studies 
amongst patients with native IHD have established that adherence of leukocytes to vascular 
endothelium is a prerequisite for transmigration of these cells and development of 
atherosclerotic plaques (194, 195). Various adhesion molecules, including the selection family 
(including P- and E-selectin) and the immunoglobulin family of molecules (including ICAM-
1 and VCAM-1), have been studied and shown to play an important role in development of 
atherosclerosis (196-198). Based on these findings, it is plausible that these molecules may 
also contribute in a similar manner to CAV development. Indeed, our results have confirmed 
that elevated levels of VCAM-1, an adhesion molecule most closely related to T-cell 
recruitment at sites of local inflammation, is associated with advanced CAV verified by IVUS 
as well as an increased inflammatory component determined by VH analysis. Hence, VCAM-
1 appears to be an important mediator of mononuclear cell recruitment and monitoring the 
expression of VCAM-1 may be a useful surrogate marker for detecting the presence of 
activated T cells and the associated risk of development of CAV and susceptible 
inflammatory lesions.  
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8. CONCLUSIONS 
This thesis has investigated the role of immunological and non-immunological markers of 
CAV amongst HTx recipients and the following conclusions can be drawn: 
 
1. NT-proBNP and CRP are not useful as markers of acute cellular rejection but both 
biomarkers, individually and in combination, predict long-term mortality amongst 
HTx recipients. Combined analysis also identifies patients at higher risk of developing 
angiographic CAV 
2. Impaired renal function is apparent in a majority of HTx recipients already at one year 
post-HTx and is associated with an increased risk of all-cause mortality. Although 
renal impairment post-HTx does not appear to increase the risk of development of 
angiographic CAV it is as associated with an increased risk of mortality attributable to 
CAV 
3. HTx recipients seropositive for T. gondii are at an increased risk of developing 
angiographically advanced CAV. Several immunoregulatory changes occur following 
T.gondii infection and these events may potentially contribute to the development of 
CAV and the increased risk of mortality 
4. Advanced CAV, determined by IVUS, is associated with an inflammatory signature 
comprising of elevated CRP, VCAM-1 and neopterin. Elevated levels of CRP and 
VCAM-1 are also associated with an increased proportion of inflammatory tissue 
determined by VH analysis. Routine measurement and monitoring of these 
inflammatory markers may represent a novel and non-invasive method of post-HTx 
risk stratification and CAV surveillance.  
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ABSTRACT  
 
We evaluated an extensive profile of clinical variables and immune markers to assess the 
inflammatory milieu associated with cardiac allograft vasculopathy (CAV) assessed by 
intravascular ultrasound (IVUS) and virtual histology (VH). 
In total, 101 heart transplant (HTx) recipients were included and underwent IVUS/VH 
examination and measurement of plasma C-reactive protein (CRP), soluble tumor necrosis 
factor receptor-1, interleukin-6, osteoprotegerin, soluble gp130, von Willebrand factor, 
vascular cell adhesion molecule-1 (VCAM-1) and neopterin. 
Mean Maximal Intimal Thickness (MIT) was 0.61±0.19 mm and mean fibrotic, fibrofatty, 
dense calcified and necrotic core components were 55±15, 14±10, 15±13 and 17±9%, 
respectively. In multivariate analysis, CRP >1.5 mg/L (OR 4.6, p<0.01), VCAM-1 >391 
ng/mL (adjusted OR 3.2, p=0.04) and neopterin >7.7 nmol/L (OR 3.8, p=0.02) were 
independently associated with MIT >0.5 mm. In a separate analysis, CRP >1.5 mg/L (OR 3.7, 
p<0.01) and VCAM-1 >391 (OR 2.7, p=0.04) were independently associated with an 
increased inflammatory component (dense calcified/necrotic core component>30%).  
Advanced CAV is associated with elevated CRP, VCAM-1 and neopterin and the two former 
biomarkers are also associated with an increased inflammatory component. Forthcoming 
studies should clarify if routine measurements of these markers can accurately identify HTx 
recipients at risk of developing advanced CAV and vulnerable lesions.  
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INTRODUCTION 
 
Cardiac allograft vasculopathy (CAV) is an important complication limiting survival after 
heart transplantation (HTx). According to international registry data 43% of HTx recipients 
have developed CAV within the first 8 years after transplantation, and it is the second leading 
cause of mortality in patients who survive the first year after HTx (1). CAV is characterized 
by diffuse intimal thickening and although the pathogenesis is not fully understood, there is a 
consensus that the process is multifactoral and likely to be mediated by a final common 
immunological and inflammatory pathway (2).  
Various studies have demonstrated that both immunological and non-immunological 
factors, such as impaired renal function (3), hyperlipidemia (4), and cytomegalovirus (CMV) 
infection (5) are associated with an increased risk of CAV development. It is believed that 
these various factors are able to trigger inflammatory responses that include cytokine 
induction and T-cell activation resulting in cell infiltration and intimal thickening. For 
example, we and others have previously demonstrated that elevated C-reactive protein (CRP) 
is associated with an increased risk of CAV development diagnosed by angiography (6, 7). 
Similarly, it has also been shown that antibodies to endothelial cells are associated with a 
higher risk of CAV (8). Such studies are important, but a single-marker approach gives a 
limited view of a complex process and does not recognize the interactions of various 
inflammatory mediators that are likely to occur in vivo. A further major limitation of these 
studies is the use of angiography to determine CAV considering it is well-established that this 
method grossly underestimates CAV diagnosis (9).  
In the present study we aimed to evaluate the relationship between a broad spectrum of 
immune markers and quantitative and qualitative CAV assessment by intravascular ultrasound 
(IVUS) and virtual histology (VH) analysis, respectively. Virtual histology is a relatively new 
technique that utilizes backscatter radiofrequency data obtained during IVUS analysis and has 
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a 94–97% ex vivo and 87–97% in vivo accuracy for characterization of four basic tissue 
components amongst patients with ischemic heart disease (10, 11). Given our limited 
understanding of the complex in vivo processes responsible for CAV, such an assessment of 
CAV tissue composition amongst HTx recipients represents a novel and potentially valuable 
tool that merits further exploration. 
The soluble inflammatory markers evaluated in this study included more general 
downstream markers of immune activation such as CRP and neopterin, being the prototypical 
acute-phase protein and marker of macrophage activation, respectively, markers of 
endothelial cell activation such as vascular cell adhesion molecule-1 (VCAM-1) and von 
Willebrand factor (vWf), more specific markers of activity in the upstream inflammatory 
pathways such as the interleukin-6 (IL-6) (i.e. IL-6 and soluble gp130) and tumor necrosis 
factor- (TNF-) [i.e. soluble TNF receptor type 1 (sTNFR-1)] systems, as well as 
osteoprotegerin (OPG), a molecule involved in bone remodeling, inflammation and coronary 
artery calcification. These various inflammatory markers reflect distinct, but potentially 
equally important, pathophysiological pathways and we sought to evaluate their relationship 
to CAV as assessed by IVUS and VH analysis. 
 
 
MATERIAL AND METHODS 
 
Patient population. In total, 101 HTx recipients attending their routine annual follow-up visit 
between November 2005 and February 2008 were prospectively included. The inclusion 
criteria were: (1) age >18 years at time of follow-up visit; (2) consent to IVUS and VH 
examination; (3) estimated glomerular filtration rate >30 ml/minute at the time of follow-up 
visit (HTx recipients with severe renal impairment do not undergo annual angiography at our 
centre unless clinically indicated). The study complies with the Declaration of Helsinki, the 
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locally appointed ethics committee approved the research protocol and informed consent was 
obtained from all patients.   
The immunosuppressive regime at our centre consists of maintenance therapy with 
cyclosporine, prednisolone and azathioprine or mycophenolate mofetil (the latter was 
implemented as protocol for patients undergoing HTx after 2001). No induction therapy is 
used at our centre and all patients receive statin therapy unless clinically contraindicated. Data 
regarding patient demographics, acute rejection episodes, medication, echocardiography 
measurements, biochemical profile [including N-terminal probrain natriuretic peptide (NT-
proBNP (12)) and uric acid], serological analysis [CMV and Toxoplasma gondii (T. gondii) 
seropositivity (13)] was available for all patients (Table 1). 
IVUS and VH acquisition. IVUS examination was performed after routine angiography 
following intracoronary administration of 200 μg nitroglycerin. A major coronary epicardial 
artery (preferentially the left-anterior descending coronary artery) was imaged using a 20 
MHz, 2.9F, monorail electronic Eagle Eye Gold IVUS imaging catheter (Volcano 
Corporation Inc, Rancho Cordova, CA) and a dedicated IVUS scanner (Volcano Corporation) 
which also allows simultaneous acquisition of VH (backscatter radiofrequency) data.  
The IVUS catheter was placed as distal as possible and automated mechanical 
pullback was performed from this start point to the ostium. IVUS images were acquired at a 
rate of 30 frames/second and a pullback speed of 0.5 mm/second resulting in 1 mm intervals 
between every 60 frames. IVUS images were stored on a CD-ROM for later offline 3D 
volumetric analysis. VH images were acquired with each heart beat which functions as a 
trigger for image acquisition and these were stored on DVD-ROM for later offline analysis.  
IVUS measurements. Semi-automated contour detection of both the lumen and external 
elastic membrane (EEM) was performed at intervals of 60 frames using dedicated software 
(QIVUS Clinical Edition, Medis Medical Imaging, Leiden, Netherlands). The longest possible 
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segment between the most distal and proximal side branch visualized in the IVUS pullback 
was analyzed for each patient. Following automatic contour detection, borders were edited 
manually by two independent operators according to the guidelines for acquisition and 
analysis of IVUS images by the American College of Cardiology and European Society of 
Cardiology (14). The IVUS analysis was performed prior to measurement of inflammatory 
markers to prevent any potential observer bias. Satisfactory IVUS recordings were available 
for all patients and a total of 4258 IVUS frames were analyzed with a median number of 42 
frames per patient. 
The following parameters were recorded for all patients using the mean result of all 
frames analyzed: (1) lumen cross-sectional area (CSA), (2) vessel CSA, (3) intimal CSA and 
(4) maximal intimal thickness (MIT). In accordance to established guidelines, the largest 
distance from the intimal leading edge to the EEM was defined as MIT (14) and advanced 
CAV was defined as MIT >0.5 mm as this has been shown to accurately predict subsequent 
mortality and non-fatal major adverse cardiac events related to CAV (15). The CSA 
measurements were utilized to calculate Total Atheroma Volume (TAV) using Simpson's 
method as well as Percent Atheroma Volume (PAV) which expresses the summation of 
atheroma areas in proportion to the EEM area using the equation: PAV =   area – 
Lumenarea)/area) x 100. Recent studies suggest that PAV has the smallest coefficient of 
variability (16, 17) and we, therefore, considered this as an additional endpoint for CAV. 
Since there is no established PAV value defining advanced CAV, we pre-specified PAV 
above the mean value as indicative of advanced CAV. In our IVUS laboratory the intra-
observer variability for both CAV endpoints (MIT and PAV) was <3%, whereas the inter-
observer variability was <5% and this is comparable to other centers (16).  
VH measurements. IVUS measurements were performed prior to VH analysis and the same 
segment length and portion that was utilized for CAV quantification (QIVUS software) was 
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utilized for qualitative assessment by dedicated VH software (pcVH, v.2.2, Volcano 
Corporation). This required initial semi-automated contour detection of all acquired frames 
captured at the top of the R-wave of the heart cycle. Satisfactory VH recordings were 
available for all patients and a median number of 176 VH frames were analyzed per patient. 
Followed manual editing of contours, stored radiofrequency data was utilized by the software 
to reconstruct tissue maps with four identifiable major components – fibrous, fibrofatty, dense 
calcified and necrotic core components – which were allocated a separate color coding in 
digitized images and expressed as a percentage of total intima area. Necrotic core component 
is composed of lipid cells, necrotic and lymphocyte remnants together with tissue 
microcalcification. Consequently, several previous studies have considered necrotic and dense 
calcified tissue to, at least partly, reflect inflammatory tissue components of the vessel wall 
being associated with a higher subsequent progression of CAV (18, 19). We defined increased 
inflammatory tissue component as necrotic and dense calcified tissue >30%. This arbitrary 
cut-off has been utilized in another other recent HTx study (19) and is supported by the results 
of other ex-vivo and in-vivo VH-IVUS studies performed amongst patients with IHD (20-23).  
Inflammatory marker analysis. Plasma samples were collected by standard venepuncture 
prior to angiography and IVUS examination. Peripheral venous blood were drawn into sterile 
blood collection tubes with EDTA as anticoagulant, immediately immersed in melting ice, 
and centrifuged within 30 minutes at 2000g for 20 minutes to obtain platelet-poor plasma. 
Plasma specimens were stored at -80°C and were thawed less than three times. 
Plasma levels of sTNFR-1, IL-6, OPG, gp130 and VCAM-1 were measured by 
enzyme immunoassays (EIA) obtained from R&D Systems (Minneapolis, MN). Plasma levels 
of neopterin were measured by EIA provided by Brahms (Henninsdorf, Germany). CRP and 
vWf were measured by EIAs as previously described (24, 25). All intra-assay and inter-assay 
coefficients of variance were <10%.  
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Statistical analysis. Analyses were performed with the SPSS statistical software (SPSS Inc. 
Chicago, IL, v.13.0) and a p-value <0.05 was considered statistically significant. Student’s t 
test was used for normally distributed continuous variables and Mann-Whitney test for other 
continuous variables. One way analysis of variance was used to compare means amongst two 
or more groups. Categorical variables were compared using the chi-square test and 
multivariate regression analysis was performed to estimate odds ratios using forward stepwise 
conditional method. Data is expressed as mean ±SD or as median (interquartile range) as 
appropriate.  
 
RESULTS 
 
The baseline characteristics of the study population are shown in Table 1.  
IVUS measurements and the occurrence of advanced CAV. The mean vessel length 
analyzed by IVUS examination was 42.0±9.8 mm and an example of an IVUS recording is 
shown in Figure 1. Mean MIT was 0.61±0.19 mm, and 47 (47%) of patients were found to 
have advanced CAV defined as MIT >0.5 mm (15). Mean PAV was 32.3±9.5% and 
normalized TAV was 4.9±2.0 mm3/mm. A relatively large HTx population was included and 
time since HTx varied considerably [median 5.0 (IQ range 3.0-9.0) years], but no significant 
difference in time since HTx was found amongst patients with MIT below and above 0.5 mm 
(p=0.65). A similar pattern was seen for the other measured IVUS parameters (vessel, lumen 
and intimal CSA, vessel and lumen volume, normalized TAV and PAV) with no relation to 
time since HTx (Table 2).  
When comparing demographic and clinical characteristics, patients with MIT >0.5 mm 
(n=47) were older, had a higher serum creatinine, displayed higher NT-proBNP levels and 
were more likely to be T. gondii seropositive (Table 1). In contrast, a past history of 
significant cellular rejection episodes (	
, impaired ventricular function as measured 
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by echocardiography and CMV seropositivity/mismatch were not associated with this marker 
of advanced CAV (Table 1). 
VH measurements. An example of an analyzed VH frame is shown in Figure 1. Fibrous 
tissue was the predominant identifiable component of the intimal area (55±15%) followed by 
very similar proportions of fibrofatty (14±10%), dense calcified (15±13%) and necrotic core 
(17±9%) tissue. (Table 3). Our data indicated increased fibrotic and less inflammatory tissue 
(dense calcified and necrotic core) with increasing time since HTx, but this association did not 
reach statistical significance (p=0.07). When evaluating demographic and clinical parameters 
we noted that increased inflammatory component was also associated with increased serum 
creatinine (p<0.01) and lower HDL levels (p<0.01), but not with any of the other parameters 
outlined in Table 1.  
Inflammatory markers. As shown in Figure 2, patients with MIT > 0.5 mm had significantly 
higher levels of CRP, sTNFR-1, VCAM-1 and neopterin as compared with those with MIT 
 . Similar significant results were found for the above inflammatory markers, in 
addition to vWf, when using PAV >32% as an alternative CAV endpoint (Figure 3). As for 
IL-6, OPG and gp130, no significant relationship was found to either MIT or PAV (Figures 2 
and 3). Patients with increased intimal inflammatory component (i.e. dense calcified/necrotic 
core >30%) also displayed significantly higher levels of CRP, sTNFR-1, VCAM-1, vWf and 
neopterin, but there was no significant relation to the other markers of inflammation (Figure 
4).  
Multivariate analysis. The variables in Table 1 found to be associated with advanced CAV 
upon univariate analysis (p<0.05) were all included in a multivariate regression analysis to 
identify independent determinants of advanced CAV (i.e. MIT >0.5 mm). CRP, sTNFR-1, 
VCAM-1 and neopterin (all significant upon univariate analysis) were included in this 
analysis and categorized according to median values. This final regression model revealed 
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that CRP >1.5 mg/L [adjusted OR 4.6 (95% CI 1.7-12.2), p<0.01], VCAM-1 >391 ng/mL 
[adjusted OR 3.2 (95% CI 1.1-9.7), p=0.04] and neopterin >7.7 nmol/L [adjusted OR 3.8 
(95% CI (1.2-11.6), p=0.02], but not sTNFR-1 [adjusted OR 1.3 (95% CI 0.2-4.8), p=0.81], 
were independently associated with MIT >0.5 mm (Table 4). Similar significant results were 
found when utilizing PAV >32% as an alternative CAV endpoint (data not shown). Notably, 
of all the included parameters, CRP was the strongest predictor of advanced CAV, and all the 
inflammatory markers were stronger predictors of CAV than all the included clinical 
parameters, except for T. gondii seropositivity (Table 4). This latter finding confirms our 
previously reported association between T. gondii seropositivity and angiographically 
diagnosed CAV (26), further underscoring that this serological risk factor may have been 
overlooked in previous studies.  
A separate multivariate analysis was performed to assess independent determinants of 
an increased inflammatory component and CRP and VCAM-1 were found to be significant 
variables with an adjusted OR of 3.7 (95% CI 1.4-9.5, p<0.01) and 2.7 (95% CI 1.1-6.9, 
p=0.04), respectively (Table 5). Elevated serum creatinine [adjusted OR 4.7 (95% CI 1.6-
14.1), p<0.01] and lower HDL levels [adjusted OR 3.7 (95% CI 1.3-10.6), p=0.01] were also 
independent predictors of an increased inflammatory component. Although univariate 
analysis revealed significantly elevated levels of sTNF-R1, vWf and neopterin amongst 
patients with an increased inflammatory component these  markers did not retain statistical 
significance in this multivariate regression model (Table 5). 
 
DISCUSSION 
 
The current study has evaluated the association between a broad profile of clinical and 
inflammatory variables and both quantitative and qualitative CAV assessment by IVUS and 
VH analysis, respectively. This is, to the best of our knowledge, the first report that shows 
that advanced CAV, as determined by IVUS, is associated with increased plasma levels of 
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CRP as well as VCAM-1 and neopterin, suggesting a pathogenic role of inflammation, 
including endothelial cell and monocyte/macrophage activation, in the development of this 
complication post-HTx. Furthermore, we found that elevated levels of CRP and VCAM-1 
were associated with an increased proportion of inflammatory tissue in the thickened intimal 
area evaluated by VH analysis, suggesting a link between systemic and local inflammation 
within coronary artery in the transplanted heart.  
CRP is considered as a stable and sensitive marker of upstream systemic inflammation 
(27). We and others have previously demonstrated in prospective studies that elevated levels 
predict development of angiographically evident CAV amongst HTx recipients (28, 29). 
Hence, it has been suggested that CRP reflects a general inflammatory state associated with 
CAV development and adverse outcome (30). Our current study extends previous studies by 
showing that elevated CRP is strongly associated with advanced CAV as measured by two 
different IVUS endpoints (MIT and PAV). Also, we show a clear relationship between CRP 
and inflammatory tissue content in the affected intima. This intimal characteristic is inherently 
regarded as a vulnerable tissue type due to increased inflammatory cells, higher lipid content, 
many necrotic cells and foam cells and a poor cellular matrix with a higher risk of thrombosis 
or rupture (31), and our finding in the present study further suggest a link between 
inflammation and this vascular phenotype. Previously, increased CRP levels have been linked 
to an inflammatory and higher risk plaque phenotype in atherosclerotic disorders (32, 33), and 
our finding suggest that a similar association may be present in CAV.
Neointimal proliferation and infiltration by macrophages is a key feature of CAV 
development and is likely to be driven by several processes including upstream cytokine 
activation (34). For example, activated T-cells release interferon- (IFN-) causing 
macrophage activation and production of growth factors, such as, platelet-derived growth 
factor (35) and insulin-like growth factor-1 (36), all of which may contribute to the 
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proliferation of neointimal cells. In the present study we have shown that plasma levels of 
neopterin, a reliable marker of monocyte/macrophage activation, also reflecting the IFN- 
mediated activation of these cells (37), is associated with quantitatively advanced CAV as 
well as an increased inflammatory component of the affected intima. Although our findings 
further support a role for monocyte/macrophage activation in the development of CAV, the 
triggers for this activation in HTx recipients requires investigation in further studies and may, 
ultimately, yield novel therapeutic targets. 
Endothelial adhesion molecules, including VCAM-1, are known to play an important 
role in the recruitment of inflammatory cells into vessel wall. Various immunological (e.g. 
CMV infection) and non-immunological risk factors (e.g. hyperlipidemia and hyperglycemia) 
are believed to contribute to CAV development via upregulation of adhesion molecule 
expression (30). Although experimental studies have demonstrated that VCAM-1 is induced 
on vascular endothelial cells in animal models of CAV (38), this has not been investigated in 
clinical studies. The current study shows that elevated plasma levels of VCAM-1 are 
independently associated with advanced CAV determined by IVUS. Furthermore, we noted 
that VCAM-1 is also associated with an increased inflammatory component determined by 
VH analysis further suggesting that recruitment of inflammatory cells via this adhesion 
molecule may play a role in the development of vulnerable and high-risk lesions.  
Our study included a heterogeneous group of HTx recipients and collected a wide 
array of recipient and donor data including acute rejection history, echocardiography data and 
a range of biochemical measurements. Time since HTx was not found to be a determinant of 
advanced CAV (defined by MIT or PAV). Although this negative association may seem 
surprising, it should be emphasized that previous reports of CAV detected in 8%, 32% and 
48% of HTx recipients at 1, 5 and 8 years post- HTx (1) are based on angiographic 
examination. It has been established that these figures are likely to be highly inaccurate as 
  13 
CAV is reported to be present in up to 75% HTx recipients already at one year post-HTx 
based on IVUS examinations (39). Tsutsui et al. (40) conducted a 5-year serial IVUS study 
and found that most intimal thickening occurred during the first two years post-HTx, with no 
significant increase beyond this period, indicating that CAV development is not a time-
dependent linear process. Li et al. (41) performed a similar study concluding that variable 
vascular remodeling patterns exist post-HTx and can influence and determine the rate of CAV 
progression. Hence, we believe our IVUS results demonstrate that the incidence and 
progression rate and composition of CAV is highly variable and individual.The cross-
sectional design is a limitation of our study and our results warrant further investigation in 
prospective follow-up studies. Characterization of tissue composition by VH analysis is a 
relatively new technological advancement and although it has been validated in several large 
studies it has important technical limitations. For example, the pathological definition of 
vulnerable plaque is a necrotic core with an overlying fibrous cap of <65 μm whereas the 
spatial resolution of VH is approximately 100–200 μm. Nevertheless, we believe our results 
are robust due to a relatively large patient population, assessment of a broad range of clinical 
and inflammatory markers and the use of both quantitative and qualitative analysis of CAV 
severity. However, based on the suggestion that most intimal thickening occurs during the 
first two years after HTx (42) future studies should also include longitudinal measurements of 
inflammatory markers to elucidate if an early inflammatory response (i.e. within the first year) 
is of more importance than a more late inflammatory response for the development of CAV. 
In contrast to the lack of association with most of the traditional risk factors for 
cardiovascular disease, we found that quantitatively advanced CAV, as assessed by IVUS, is 
associated with an inflammatory signature comprising of elevated CRP, VCAM-1 and 
neopterin. Although these markers are robust markers of inflammation, reflecting upstream 
inflammatory activity, they are also, at least partly, complementary and reflect different arms 
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of the immune system. Furthermore, elevated levels of CRP of VCAM-1 are associated with 
an increased proportion of necrotic core tissue determined by VH analysis. Forthcoming 
studies should clarify if routine measurements of these markers can allow accurate 
identification of HTx recipients at risk of developing quantitatively advanced CAV and 
vulnerable lesions with an increased necrotic component.  
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Table 1. Demographic and Clinical Characteristics of the Study Population (n=101). 
Characteristic Overall MIT 0.5mm 
(n=54) 
MIT >0.5 mm 
(n=47) 
p-value 
Demographics     
Recipient age (yrs) 60 (52-65) 57 (51-63) 63 (53-67) 0.05 
Recipient male gender 87 (86%) 45 (83%) 42 (89%) 0.38 
Medical history     
Time since HTx (yrs) 5.0 (3.0-9.0) 6.0 (2.8-8.0) 6.0 (3.0-10.0) 0.65 
IHD as etiology for HTx 43 (43%) 23 (43%) 20 (43%) 0.99 
Hypertension  79 (78%) 42 (78%) 37 (79%) 0.91 
Diabetes mellitus 10 (10%) 3 (6%) 7 (15%) 0.12 
Current smoker  29 (29%) 16 (30%) 13 (28%) 0.83 
Cellular rejection 	
 31 (31%) 17 (31%) 14 (30%) 0.85 
Medication     
Cyclosporine 99 (98%) 54 (100%) 45 (96%) 0.13 
Tacrolimus 2 (2%) 0 (0%) 2 (4%) 0.13 
Prednisolone  99 (98%) 52 (96%) 47 (100%) 0.18 
Azathioprine 49 (49%) 28 (52%) 21 (45%) 0.47
Mycophenolate mofetil* 42(42%) 23 (43%) 19 (40%) 0.83 
Beta-blocker 21 (21%) 9 (17%) 12 (26%) 0.27 
Calcium channel blocker 32 (32%) 21 (39%) 11 (23%) 0.10 
Angiotensin converting enzyme 
inhibitor/receptor antagonist 
41 (41%) 20 (37%) 21 (45%) 0.44 
Diuretic  20 (20%) 7 (13%) 13 (28%) 0.07 
Statin 89 (88%) 46 (85%) 43 (92%) 0.33 
Echocardiography data     
Left ventricular diameter systole (cm) 3.2±0.6 3.2±0.5 3.1±0.6 0.76 
Left ventricular diameter diastole (cm)  4.9±0.6 4.8±0.5 4.9±0.6 0.68 
Interventricular septal thickness  
diastole (cm) 1.1±0.2 1.0±0.1 1.1±0.2 
0.23 
Left ventricular posterior wall thickness 
diastole (cm) 1.0±0.2 0.9±0.2 1.0±0.3 
0.09 
Fractional shortening (%)  35.6±8.1 34.6±7.6 36.8±8.5 0.18 
Biochemical data      
Total cholesterol (mmol/L) 5.2±1.0 5.2±1.1 5.2±1.0 0.98 
HDL (mmol/L) 1.8± 0.5 1.9±0.6 1.7±0.4 0.06 
LDL (mmol/L) 3.1±0.8 3.1±0.9 3.2±0.8 0.74 
Triglycerides (mmol/L) 1.4±0.9 1.3±0.7 1.6±1.0 0.07 
Serum creatinine (μmol/L) 112±30 106±25 119±33 0.02
NT-proBNP (pmol/L) 38 (24-81) 33 (16-61) 41 (29-95) <0.01 
Serum uric acid (μmol/L) 425±99 398±99 457±88 0.11 
Serological data     
CMV IgG seropositivity 69 (68%) 41 (76%) 28 (60%) 0.08 
Recipient/donor CMV mismatch (R-/D+) 18 (18%) 7 (13%) 11 (23%) 0.17
T.gondii IgG seropositivity 27 (27%) 9 (17%) 18 (38%) 0.02 
Donor characteristics     
Donor age (yrs) 35 (21-43) 28 (20-41) 38 (23-48) 0.08 
Donor male gender  35 (35%) 19 (35%) 16 (34%) 0.90 
Ischemic time (min) 174 (65-206) 179 (74-206) 169 (59-206) 0.36 
Data are reported as mean±SD, median and interquartile range or as percent frequency, as appropriate. 
IHD=ischemic heart disease; NT-proBNP=N-terminal probrain natriuretic peptide; CRP=C-reactive 
protein; CMV=cytomegalovirus; T. gondii=Toxoplasma gondii.  
*Mycophenolate mofetil was first introduced at our centre (as an alternative to azathioprine) amongst 
patients undergoing HTx from 2002 onwards. 
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Table 2. Results of IVUS Analysis for the Entire Study Population According to Time after 
Heart Transplantation (HTx). 
   Time since HTx (years)  
IVUS parameter Overall  (n=29) 4-6 (n=28)  (n=44) p-value 
Segment length (mm)* 42.0±9.8 40.2±8.6 42.2±8.7 43.4±11.1 0.41 
Vessel CSA (mm2) 14.9±5.0 14.2±4.0 14.0±3.2 16.1±6.3 0.13 
Lumen CSA (mm2) 10.2±4.0 9.4±2.9 9.8±3.1 10.9±5.0 0.29 
Intimal CSA (mm2) 4.7±1.9 4.7±1.9 4.2±1.5 5.3±2.2 0.09 
MIT (mm) 0.61±0.19 0.61±0.19 0.58±0.18 0.63±0.19 0.45 
Total vessel volume (mm3) 641.8±269.1 590.9±217.5 595.0±182.3 694.9±327.8 0.12 
Total lumen volume (mm3) 436.5±202.7 390.7±150.7 422.4±154.3 466.1±245.0 0.20 
Normalized TAV (mm3/mm) 4.9±2.0 5.0±2.0 4.2±1.5 5.2±2.0 0.09 
PAV (%) 32.3±9.5 33.2±9.0 30.5±10.1 32.9±9.4 0.49 
*Absolute segment length is equal to number of frames analyzed (slice thickness=1 mm).  
CSA = cross-sectional area, PAV = percent atheroma volume, TAV = total atheroma volume, 
MIT = maximal intimal thickness 
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Table 3. Results of Virtual Histology Analysis for the Entire Study Population According to 
Time after Heart Transplantation (HTx). 
   Time since HTx (years)  
Tissue type (%) Overall 	
 4-6 (n=28) 	 p-value 
Fibrous 55±15 54±17 50±16 58±11 0.15 
Fibrofatty 14±10 14±9 10±9 16±11 0.12 
Dense calcified 15±13 14±13 19±16 12±10 0.13 
Necrotic core 17±9 17±10 20±10 14±8 0.07 
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Table 4. Multivariate Logistical Regression Analysis of Determinants of Advanced Allograft 
Vasculopathy as defined by Maximal Intimal Thickness > 0.5 mm. 
Risk factor  Odds ratio 95 % CI p-value 
Age >60 years 1.4 0.6-3.7 0.43 
NT-proBNP >39 pmol/L 2.7 0.9-8.1 0.07 
Serum creatinine>112 μmol/L 0.7 0.2-2.7 0.63 
Recipient T. gondii seropositive status 5.0 1.5-17.3 0.01* 
CRP >1.5 mg/L 4.6 1.7-12.2 <0.01*
sTNFR-1 >1996 pg/mL 1.3 0.2-4.8 0.81 
VCAM-1 >391 mg/mL 3.2 1.1-9.7 0.04* 
Neopterin >7.7 nmol/L 3.8 1.2-11.6 0.02* 
 
CRP=C-reactive protein, sTNFR-1=soluble tumor necrosis factor receptor-1, 
VCAM=Vascular cell adhesion molecule-1, NT-proBNP=N-terminal probrain natriuretic 
peptide, T. gondii= Toxoplasmosis gondii.  
* denotes statistically significant values (<0.05) 
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 Table 5. Multivariate Logistical Regression Analysis of Determinants of Increased Intimal  
Inflammatory Component (>30% dense calcified/necrotic core component). 
Risk factor  Odds ratio 95 % CI p-value 
Serum creatinine >112 μmol/L 4.7 1.6-14.1 <0.01*
HDL <1.8 mmol/L 3.7 1.3-10.6 0.01* 
CRP >1.5 mg/L 3.7 1.4-9.5 <0.01*
sTNFR-1 >1996 pg/mL 1.5 0.9-2.0 0.30 
VCAM-1 >391 mg/mL 2.7 1.1-6.9 0.04* 
vWf > 121 AU 1.2 0.5-2.6 0.58 
Neopterin >7.7 nmol/L 1.8 0.8-8.2 0.42 
 
CRP=C-reactive protein, sTNFR-1=soluble tumor necrosis factor receptor-1, 
VCAM=Vascular cell adhesion molecule-1 vWf= von Willebrand factor 
* denotes statistically significant values (<0.05) 
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FIGURE LEGENDS 
 
Figure 1. Example of an intravascular ultrasound and virtual histology recording.  
Upper panel: A longitudinal segment of an intravascular (IVUS) recording obtained by the 
Volcano scanner and an example of a transverse IVUS frame manually edited after semi-
automated contour detection.  Red marking = lumen contour (LC), green marking = external 
elastic membrane (EEM), blue line = level for the transverse image. 
Lower panel: Analysis of a virtual histology frame obtained at the time of IVUS acquisition. 
Analysis of radiofrequency data following contour detection provides color coded tissue 
component characterization where green is fibrous, light green is fibrofatty, white is dense 
calcified and red is necrotic core component.   
 
Figure 2. Immune marker profile according to Maximal Intimal Thickness measured by 
intravascular ultrasound analysis. Advanced cardiac allograft vasculopathy as defined by 
Maximal Intimal Thickness (MIT) >0.5 mm was associated with elevated levels of C-reactive 
protein (CRP), soluble tumor necrosis factor receptor-1 (sTNFR-1), vascular cell adhesion 
molecule–1 (VCAM-1) and neopterin. There was no significant difference in levels of 
interleukin-6 (IL-6), osteoprotegerin (OPG), soluble gp130 and von Willebrand factor (vWf) 
between the two groups.   
 
Immune marker profile according to Percent Atheroma Volume measured by 
intravascular ultrasound analysis. Advanced cardiac allograft vasculopathy as defined by 
Percent Atheroma Volume (PAV) >32% was associated with elevated levels of C-reactive 
protein (CRP), soluble tumor necrosis factor receptor-1 (sTNFR-1), von Willebrand factor 
(vWf), vascular cell adhesion molecule–1 (VCAM-1) and neopterin. There was no significant 
difference in levels of interleukin-6 (IL-6), osteoprotegerin (OPG) and soluble gp130 between 
the two groups.   
  21 
Figure 4. Immune marker profile according to intima inflammatory component 
determined by VH analysis. An increased intima inflammatory component (necrotic core 
and dense calcium >30%) was associated with elevated levels of C-reactive protein (CRP), 
soluble tumor necrosis factor receptor-1 (sTNFR-1), von Willebrand factor (vWf), vascular 
cell adhesion molecule–1 (VCAM-1) and neopterin. There was no significant difference in 
levels of interleukin-6 (IL-6), osteoprotegerin (OPG) and soluble gp130 between the two 
groups.   
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